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FOREWORD
It is our pleasure and a great honour to introduce to you
this volume containing the Proceedings of the Regional In-
ternational Bioethics Conference – Genetic Tests for Health
Purposes in Central and Eastern Europe, which took pla-
ce in Bratislava on May 29 – 30, 2014, as an activity sponso-
red by the Committee on Bioethics (DH-BIO) and its Sec-
retariat within the program DEBRA.      
The truly unique features of the conference were at least
two-fold: 1. the main topic chosen was dealing with the
rapidly, exponentially growing area of contemporary me-
dicine and health care – medical genetics in general, and
with one of its most powerful working arms – genetic
tests in particular, all this being dealt with from a specific
viewpoints of international bioethics and bio-law; 2. the
participants – invited delegates to the conference, were
stemming from the countries of Central and Eastern Eu-
rope that have shared multifaceted, complex, and rather
similar experiences of the relatively recent past, and, mo-
re importantly, also more or less similar present date and
emerging challenges, when aligning their medical prac-
tices and health care systems to face and deal with their
inherent advances and shortcomings in their continuous
efforts to implement and develop medical genetics as an
integral part of those. All this to provide also the neces-
sary respect and protection of human dignity and rights
for their citizens, especially the patients and their rela-
tives, while implementing eagerly and wisely these new
powerful technologies and sciences for the individual
and common good, i.e. for the purposes of protection,
and also for development of a good health, and, hopeful-
ly, of a good life. 
The conference participants greatly benefited from the
state-of-the-art inputs provided by the distinguished invi-
ted speakers, and also from their own, brought in, con-
crete inputs, concerning the varying situations in their
respective countries that they were able to share and dis-
cuss with their colleagues from, sometimes, very interes-
ting and useful new angles. The space and attention that
were put to this exchange and common discussion part
of the meeting did proved itself being both very interes-
ting and useful. And also encouraging. Especially, when
facing the long lasting, country-specific situations, where
the legal, or educational-informational progress is very
difficult to achieve, even with much extraordinary effort
and additional expert work, let aside lagging behind (in
comparison with some other parts of Europe) in respecti-
ve technological, organizational and health policy realms.   
It is our duty and honour to thank cordially to all contri-
butors to this volume, who were kind enough to provide
their original manuscripts, as well as to the delegations
that were able to share the information and insight for
the better as seen from their countries’ perspectives. 
We would also like to thank the Secretariat of DH-BIO for
an excellent help and support both in organizing the
meetings itself, but also in putting together this publica-
tion.  
We hope, dear readers, that you find the following pages
interesting and useful. 
Jozef Glasa & Helena Glasová, volume editors 
Bratislava, October 2014
OPENING ADDRESS
Laurence LWOFF
Bioethics Unit, Council of Europe, Strasbourg, France
Dear members of the Honorary Presidium 
of the Conference, 
Honorable members of the countries’ delegations, 
Distinguished conference speakers and chairs, 
Ladies and gentlemen, 
It is both an honor and a pleasure to be here today, in Bra-
tislava, as the Representative of the Council of Europe, at
the opening of this Conference. And this in many res-
pects.
This year we are celebrating the 15th anniversary of the ent-
ry into force of the Convention on Human Rights and Bio-
medicine (Oviedo Convention). Slovakia was one of the
first countries to ratify the Convention enabling it to en-
ter into force.  
The very first regional bioethics conference sponsored by
the Council of Europe took place in Bratislava already in
January 1992. Since then Slovakia has greatly contributed
to raising awareness on and to facilitating implementa-
tion of the Convention by hosting, with this event, already
six international conferences, the first one in 1999, focu-
sing on the Convention and its additional protocols, in-
cluding, in 2002, a conference on ethics of human genetics. 
Genetic testing will be at the center of this conference
organized under the auspices of Mrs. Zuzana Zvolenská,
minister of health, represented here by Dr. Ján Rosocha,
whom I wish to thank particularly. But also this confe-
rence is held with the support of the Slovak Medical Asso-
ciation, the Slovak Medical University in Bratislava, and
of the Institute of Medical Ethics and Bioethics n.f. 
I wish to thank all of them for their involvement in the
organization of this conference, together with the Bio-
ethics Unit of the Council of Europe in the framework of
its cooperation activities (Program DEBRA). 
Genetics is clearly the field, which has seen very impor-
tant developments, in particular in the last 15 years. A lot
of benefits for human health are expected from these
positive achievements of science and technology. Re-
search in this field is the source of a great hope for better
understanding of etiology of so many diseases and develop-
ment of appropriate treatment and prevention means.
Even though the situation in European countries may va-
ry, medical genetics and genetic testing are becoming
more and more an integral part of the health care. The
applications of genetics expand also much outside the
medical field. 
But medical genetics and genetic testing provides for
greater possibility to enter into the biological intimacy of
all human beings, raising concerns about privacy and
possible discrimination on the basis of an individual’s
genetic characteristics. 
All these issues needed to be addressed to ensure proper
protection of human rights enabling thereby to promote
proper use of this important tool for the benefit of hu-
man health.  
This was the main objective of the Additional Protocol to
the Convention on Human Rights and Biomedicine on
Genetic Tests for Health Purposes elaborated by the Coun-
cil of Europe and opened for signature in 2008. This
Protocol complements the Oviedo Convention, develo-
ping further this legal corpus, which has now gain a refe-
rence status at the European, but also at the global level. 
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This Protocol, for the drafting of which the Committee
on Bioethics of the Council of Europe benefited a lot from
the work already done by several professional associa-
tions and some international organizations, in particular
the European Society of Human Genetics, was unani-
mously adopted by the Committee of Ministers and thus
opened for signature and ratification. It already had influ-
enced several national legislations that were in develop-
ment during and after the Protocol’s adoption. 
This conference will provide an opportunity to examine
developments in genetic testing and the human rights
challenges they have raised. An opportunity, also to bet-
ter understand the possible difficulties encountered, in
particular in the Central and Eastern Europe, in dealing
with those challenges, which are addressed in the Addi-
tional Protocol. 
Taking into account these problems, it is particularly
important for the development of legislation and good
practices that are respectful of the fundamental values,
on which the provisions of the Protocol are based. I trust
that this symposium will contribute to the achievement
of that objective and I wish to thank in advance the spea-
kers, who have agreed to share their knowledge, as well
as the participants for their input and contribution in the
discussion that will take place during these two days. 
Thank you for your attention! 
Correspondence to: Mrs. Dr. Laurence Lwoff, Head, Bioethics
Unit, Human Rights Policy and Development Department, Hu-
man Rights Directorate, Directorate General I, Council of Euro-
pe, F-67075 Strasbourg Cedex, France, 
e-mail: laurence.lwoff@coe.int
GENETIC TESTS – OVERVIEW 
OF THE SITUATION IN THE LIGHT OF 
THE TECHNOLOGICAL DEVELOPMENTS: 
AN EXAMPLE OF THE CZECH REPUBLIC
Milan Macek
Department of Biology and Medical Genetics, Charles
University Prague, 2nd Faculty of Medicine and University
Hospital in Motol, Prague, Czech Republic
Extended Abstract
The main aim of the presentation was to provide an over-
view on the increasing disparities in terms of the rapid
production of biomedical data, by e.g. next generation
sequencing technologies (NGS) in genetics/genomics,
and lagging clinical validity and utility of such data within
the domain of health care. The falling price of DNA se-
quencing which now exceeds Moore’s law for semicon-
ductors and the relative rapid increase in genetic testing
outside of the traditional “germ line” genome domain i.e.
testing of somatic mutations in oncology, minimal resi-
dual disease in hematooncology, microbiology, creates
strong pressures on finite resources in all solidarity prin-
ciple based European health care systems. Moreover, so-
me low-resourced countries are in the risk that they will
be completely left out of the “omics” biomedical revolu-
tion and are increasingly lagging behind with relevant
health care applications. 
In the absence of regulation every medical device (e.g. se-
quencer) will “find its patient” and rapid commercialisation
of diagnostic services compounds the situation by increa-
singly applied “profit-oriented” testing and unwillingness
to share data financed from public health care funds. A re-
cent study carried out in Germany found out that up to
70% of medical indications for genetic testing were not
substantiated by evidence based approaches, while in most
other countries the situation remains unmapped. 
Very often genetic testing is used as a last resort when
standard differential diagnostic processes had been exhaus-
ted. This “ex vacuo” approach in very rare diseases runs
the risk that even at high sensitivity and specificity of the
test applied its outcomes could be biased by random mis-
takes appearing at a higher rate than the prevalence of
the disorder under examination. Very good examples of
incidental findings come from other fields, such as radio-
logy (e.g. from MRI scans), where duties “to care and do
no harm” in medicine may lead to increase in subsequent
diagnostic procedures and thus also in costs. 
Another important concern is the fact that European cli-
nical genetic services are understaffed (clinicians, gene-
tic counsellors, nurses), and there are marked disparities
between various countries. The European Society of Hu-
man Genetics (www.eshg.org) is monitoring genetic ser-
vices provision in Europe on its website. 
The Czech Republic could be used as an example for the
remainder of Central and Eastern Europe. On the positive
side medical and laboratory genetics are well recognised
professional specialities, with board exams, medical socie-
ties and a thriving state and private sectors, mostly ope-
rating according to European guidelines and recommen-
dations. Law No. 96/2001Coll. codified the Oviedo conven-
tion within the Czech legal system. Law No. 373/2011
Coll. is specific for genetic testing and has adopted most
of the provisions of the Additional protocol on genetic
testing for health care purposes of the Council of Euro-
pe, except for clinical utility clause, which was dropped
at the last minute by the Parliament during examinations
of the draft proposal prepared by the Czech Society of Me-
Article 1 – Object and purpose
Parties to this Protocol shall protect the dignity and iden-
tity of all human beings and guarantee everyone, without
discrimination, respect for their integrity and other rights
and fundamental freedoms with regard to the tests to
which this Protocol applies in accordance with Article 2.
Article 2 – Scope
1 This Protocol applies to tests, which are carried out
for health purposes, involving analysis of biological samp-
les of human origin and aiming specifically to identify
the genetic characteristics of a person which are inheri-
ted or acquired during early prenatal development (herei-
nafter referred to as “genetic tests”).
2 This Protocol does not apply:
a) to genetic tests carried out on the human embryo or 
foetus;
b) to genetic tests carried out for research purposes.
3 For the purposes of paragraph 1:
a) “analysis” refers to:
i.    chromosomal analysis,
ii.  DNA or RNA analysis,
iii. analysis of any other element enabling informa-
tion to be obtained which is equivalent to that ob-
tained with the methods referred to in sub-parag-
raphs a.i. and a.ii.;
b) “biological samples” refers to:
i. biological materials removed for the purpose of the 
test concerned,
ii. biological materials previously removed for another
purpose.
Additional Protocol to the Convention on Human Rights and Biomedi-
cine, concerning Genetic Testing for Health Purposes (2008)
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dical Genetics. Examples of misuse of genetic testing and
the lack of legal support for revision processes carried
out in response by the Czech health insurance companies
were given. The aforementioned professional association
published in 2007 an open editorial in the most of count-
ry’s medical journals warning against the “misuse of ge-
netic testing and potential for discrediting of the entire
profession”. Based on well publicised cases of misuse of ge-
netic testing, where suspicions even ran very high within
the political class (investigation is still ongoing), the Czech
Ministry of Health started the work on necessary revi-
sions of the Law No. 373/2011Coll. §28-29 in Spring 2014
in order to render legal safeguards for responsible and
evidence-based provision of the modern genomic tech-
nologies within the national health care. Distinction has
been made between trans-generational and intra-gene-
rational aspects of medical genetic services, their various
roles, and associated necessity for specific legal provi-
sions for patients and their families. 
M.M. was supported by the Czech Ministry of Health: 00064203 –IP6003,
CZ.2.16/3.1.00/24022, RD-connect.eu (FP7-305444) and Norway Grants
(NF-CZ11-PDP-3-003-2014).
Correspondence to: Prof. Milan Macek, MD, D.Sc., Department
of Biology and Medical Genetics, 2nd Faculty of Medicine and Uni-
versity Hospital in Motol, V Úvalu 84, CZ-150 06 Prague 5, Czech
Republic, 
e-mail: milan.macek.jr@ lfmotol.cuni.cz
MEDICAL GENETICS AND HEALTH CARE 
SERVICES
Borut Peterlin
Clinical Institute of Medical Genetics, University Medical
Center Ljubljana, Ljubljana, Slovenia
Introduction
The Health for Growth Program, the third multi-annual
program of the European Union in the field of health (pe-
riod 2014-2020) focuses, among other issues, on the de-
velopment of innovative and sustainable health care sys-
tems, prevention of diseases, and on increasing the access
to health care (1). 
All mentioned areas are very relevant to the field of gene-
tic services provision. The aim of genetic services is to
respond to the needs of individuals and families who are
threatened by a genetic disease. In particular, to their wish
to know whether they are at risk of developing or trans-
mitting a genetic disease (2). Rare diseases affect between
27 and 36 million Europeans and it is estimated that about
80% of rare diseases could be attributed to the genetic
etiology. Rare diseases are characterized by several chal-
lenges: the diagnostic process is often complex, time-
consuming and painful to the patient; the genetic infor-
mation might not always be sufficiently and clearly com-
municated to the patients and their families. Health sys-
tems should therefore improve the access to genetic ser-
vices, implement systems for quality assurance, and trans-
late wisely new technologies into daily clinical practice.
Access to genetic services
Access to genetic services depends on several factors,
including the capacity of medical professionals to recog-
nize a potential genetic etiology and to refer patients to
genetic services, as well as on capabilities and capacities
of the genetic services to provide adequate service.
There is sufficient evidence to say that medical specia-
lists, including general practitioners, gynecologists, and
pediatricians feel the need to improve their competen-
cies in genetic medicine. Medical genetics education focu-
sed upon different medical professionals target groups
could contribute in an important manner to the improve-
ment of referrals of patients and family members for ge-
netic counseling and testing (3).
On the other hand, according to the Orphanet (4), 82% of
EU member countries cover genetic testing of less than
500 diseases out of more than 3000 that have been asso-
ciated with human diseases so far (5). This implies that
genetic diagnosis in the majority of EU member count-
ries, especially the smaller ones, importantly depend on
the cross-border access to the genetic services. In several
of them, more so in the Eastern and Southern European
countries, the national health care systems have not estab-
lished pathways to comprehensive genetic diagnostics in
spite of the favorable EU policy background – Directive
on the application of patient’s rights in cross-border health-
care (6).
Both the improvement of education and competencies
of the medical professionals and of the capabilities of the
genetic services, do present important opportunities to
assure the appropriate access to genetic medical services.
Quality of genetic services
Accreditation and certification of genetic services are im-
portant means to ensure and control their quality. Inter-
national quality standards on the technical competence
Article 3 – Primacy of the human being
The interests and welfare of the human being con-
cerned by genetic tests covered by this Protocol shall
prevail over the sole interest of society or science.
Article 4 – Non-discrimination and non-stigmatisation
1 Any form of discrimination against a person, either
as an individual or as a member of a group on grounds
of his or her genetic heritage is prohibited.
2 Appropriate measures shall be taken in order to pre-
vent stigmatisation of persons or groups in relation to
genetic characteristics.
Article 5 – Quality of genetic services
Parties shall take the necessary measures to ensure that
genetic services are of appropriate quality. In particu-
lar, they shall see to it that:
a) genetic tests meet generally accepted criteria of scien-
tific validity and clinical validity;
b) quality assurance programme is implemented in
each laboratory and that laboratories are subject to regu-
lar monitoring;
c) persons providing genetic services have appropriate
qualifications to enable them to perform their role in
accordance with professional obligations and standards.
Article 6 – Clinical utility
Clinical utility of a genetic test shall be an essential cri-
terion for deciding to offer this test to a person or a
group of persons.
Additional Protocol to the Convention on Human Rights and Biomedi-
cine, concerning Genetic Testing for Health Purposes (2008)
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of medical laboratories (ISO15189) have been issued,
and the schemes for external quality assessment (EQA)
in genetic testing have been developed. Nevertheless, ac-
cording to Orphanet/EuroGenetest database, only 11% of
EU laboratories providing genetic tests are effectively
accredited, and only 33% participated in at least one EQA
scheme in 2011 (7). Genetic services quality committee
at the European Society of Human Genetics is currently
launching a new pilot project focused on the quality
assessment of genetic counseling services.
Introduction of clinical genomics  
into the health service
New genetic technologies, especially Next Generation
Sequencing (NGS) applications and array-based techno-
logies are being increasingly used in the clinical diagnos-
tics. While introduction of new technologies into the cli-
nical laboratories presents a significant cost in terms of
equipment and personnel, as well as additional clinical
applications, new diagnostic approaches significantly
increase sensitivity of genetic testing. Classical genetic
testing for several disorders comprised of testing several
genes (in succession), which resulted in a high price of
genetic testing; NGS applications enable testing for tenths
of genes or even all genes in  the genome (exome) in one
test and has the potential to significantly improve the
yield and reduce the cost of genetic testing. Exome/ge-
nome sequencing applications also provide means to test
potentially any of the known gene – disease associations,
which significantly increases the number of diseases that
can be tested in the single laboratory.
There are, however, still several challenges in terms of
clinical implementation of NGS applications: there is lack
of standardization (8) and clinical guidelines, of the best
practices in terms of informed consent procedures and in-
cidental findings management (those are being developed
at present). And there is as yet also somewhat insuffi-
cient availability of the necessary equipment and exper-
tise in some regions/countries/health care facilities.
Development of future genetic services
Future organization of genetic services needs to cope with
increased demand thereof, both in terms of genetic tes-
ting and genetic counseling, and of an effective transla-
tion of new genome technologies into the clinical prac-
tice. Multidisciplinary collaboration among geneticists
and other medical specialists needs to be further deve-
loped, and an integration of medical genetics into prima-
ry care is expected. Reconfiguration of professional roles
both for geneticists and for other medical specialists will
be needed for an adequate provision of future genomic
medicine. In this process, several barriers will need to be
overcome, including existing professional boundaries,
inadequate professional development schemes, and a lack
of necessary preparedness of the health care system.
To assure sustainability of health care systems, a thought-
ful prioritization of genetic testing will be necessary.
Prioritization might be based on the usefulness of a test
with regard to the patient care, including treatment op-
tions, potential to improve quality of life and to extend
life expectancy, as well as on social factors.
There is also a clear need for adoption of sound and effec-
tive health policies, legislative and other measures that are
necessary for developing of a coherent and comprehen-
sive national frameworks for genetic services, as suggested
in the Council of Europe recommendation on the impact
of genetics on the organization of health care services and
on training of the health care professionals (9).
Conclusions
Existing challenges in terms of access to genetic services
of an appropriate quality, as well as of successful transla-
tion of the more efficient, novel genomic technologies in-
to the mainstream medicine do require an adequate con-
certed action of several key stakeholders; sound and wi-
dely accepted international professional and policy re-
commendations might considerably facilitate the process.
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Abstract* 
The paper gives an overview of the most important practi-
cal challenges of the implementation of genetic services
within the contemporary health care systems in Europe.
The increasing availability of modern high throughput la-
boratory technologies operating at progressively decrea-
sing costs per a parameter measurement provides for a con-
siderable increase of genetic data and knowledge. Avai-
lable genetic services are in many places not fully able to
meet these novel opportunities and growing demands. New
approaches need to be sought and implemented within
the resources stricken health care systems to enable a suc-
cessful and sustainable implementation of genetic/ge-
nomic medicine in contemporary and future health care
to meet properly the patients health needs in effective
diagnostics, treatment, and prevention.  
Key words: genetic medicine, health care, sustainability,
efficacy, public health
Abstrakt*
Práca poskytuje prehľad najdôležitejších praktických prob-
lémov spojených s implementáciou genetických služieb v
rámci súčasných zdravotníckych systémov v Európe. Na-
rastajúca dostupnosť moderných vysoko efektívnych lab-
oratórnych technológií za súčasne sa znižujúcej ceny jed-
notlivého stanovenia zapríčiňuje značný nárast genetic-
kých údajov a poznatkov. Súčasné genetické služby v niek-
torých prípadoch nie sú schopné v plnej miere udržať krok
s týmito novými možnosťami a narastajúcimi požiadavka-
mi. Je potrebné hľadať a uplatňovať nové prístupy, ktoré
umožnia vo finančne obmedzených podmienkach zdravot-
níckych systémov úspešnú a udržateľnú implementáciu ge-
netickej/genomickej medicíny v súčasnej a v budúcej zdra-
votnej starostlivosti, aby sa naplnili potreby pacientov v ob-
lasti efektívnej diagnostiky, liečby a prevencie.  
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Introduction
Since 2007 various commercial companies have started to
advertise and sell genetic tests directly to consumers. (1)
Based on notions of autonomy, empowerment, preven-
tion, convenience, and privacy, those companies have
usually emphasized that individuals should have a more
active role in the access to genetic tests and in the sto-
rage and protection of their genetic information. More-
over companies have underlined the empowering side,
as this would provide provides “the foundation for truly
personalized medicine in which individuals are empowe-
red not only with self-knowledge of their genetic risk,
but also with the ability to take informed actions to pre-
vent disease and preserve health”(2).
Direct-to-consumer (DTC) genetic testing encompasses
different situations. Firstly, it refers to a situation of “adver-
tising of such tests directly to the public, with the actual
ordering of the investigation and receipt of results invol-
ving a health care provider”. Secondly, it refers to the si-
tuation “where, in addition to advertising to the public,
the request for testing is initiated by the patient and re-
sults are, in turn, provided directly to the patient, indepen-
dently of the person’s usual medical practitioner.” (3)
Also the report of the Human Genetics Commission inclu-
ded in their analysis situations where “tests are commis-
sioned by the consumer but where a medical practitioner
or health professional is involved in the provision of the
service.” (4) This inclusion is important as not all con-
cerns with regard to DTC genetic testing are removed if
a medical practitioner is involved somewhere in the pro-
cess of ordering a genetic test. (5)
The current offer of DTC genetic tests is broad, and inc-
ludes both health-related and non-health-related tests. At
the level of health-related tests various companies offer
susceptibility tests for common complex disorders, carrier
tests for autosomal recessive disorders, pharmacogenomic
tests, and so-called ‘lifestyle’ tests. Non-health-related
tests include testing for traits, such as athletic perfor-
mance, ancestry and genealogical tests, as well as paterni-
ty tests. Over the years the number of disorders and traits
analysis has often been increasing. Moreover, at the tech-
nical level instead of analysing single nucleotide poly-
morphisms resulting from genotyping, companies are
currently starting to offer whole genome or exome se-
quencing.
This paper aims to provide an overview of (a) the con-
cerns related to DTC genetic testing and (b) the regulatory
approaches that have been presented and/or implemented.
Limitations and risks
The offer of DTC genetic tests has led to various concerns.
Especially, various professional societies (6-10), National
Bioethics Committees (11-14) or national advisory com-
mittees (4;15) addressed recently the topic. At the Euro-
pean level, the European Academies of Science and the
Federation of European Academies of Medicine have also
published a report on this issue. (16) In this article fol-
lowing concerns will be highlighted: 1) Limited clinical
validity and utility; 2) Potential negative psychological
impact; 3) Absence of pre- and post-test counseling and
an adequate informed consent procedure; 4) Absence of
individualized medical supervision; 5) Potential burden
on the healthcare system.
Limited clinical validity and utility
When assessing the quality of genetic tests, the ACCE mo-
del has been proposed as a useful tool. (17;18) This tool
integrates a set of 44 questions that related to the analyti-
cal validity (i.e. how accurately and reliably can the test
measure the genotype of interest?), clinical validity (i.e.
how consistently and accurately is the test able to detect
or predict the intermediate or final outcomes of inte-
rest?), clinical utility (i.e. how likely is the test is to signifi-
cantly improve patient outcomes?), and the ethical, legal
and social issues refer to the ethical, legal, and social imp-
lications that may arise in the context of using the test.
In view of these criteria, many commentators have criti-
cized the limited clinical utility and validity of DTC gene-
tic tests. (19-23). As for example, Janssens et al. (24) with
regard to the provision of risk profiles for common
complex disorders advanced that “there is insufficient evi-
dence to conclude that genomic profiles are useful in
measuring genetic risk for common diseases or in develo-
ping personalized diet and lifestyle recommendations for
disease prevention.” Common complex disorders develop
due to a complex interaction of multiple genes and envi-
ronmental factors. Each genetic and environmental factor
often contribute only a modest fraction of the risk of de-
veloping the disorder, therefore, making it extremely dif-
ficult to assign an accurate and meaningful degree of risk
to each different factor. In the same line, the Government
Accountability Office concluded that the tests they analy-
zed “mislead the consumer by making health-related pre-
dictions that are medically unproven and so ambiguous
that they do not provide meaningful information to con-
sumers.” (25)
On November 22, 2013 the US Food and Drug Administ-
ration (FDA) ordered the US-based company 23andme to
stop marketing its “Personal Genome Service” (PGS), a
health-related direct-to-consumer (DTC) genetic testing ser-
vice (26). In their warning letter, the FDA showed espe-
cially concerns about the health claims that were made
by this company: “Some of the uses for which PGS is in-
tended are particularly concerning, such as assessments
for BRCA-related genetic risk and drug responses (e.g.,
warfarin sensitivity, clopidogrel response, and 5-fluorou-
racil toxicity) because of the potential health consequen-
ces that could result from false positive or false negative
assessments for high-risk indications such as these. For
instance, if the BRCA-related risk assessment for breast
or ovarian cancer reports a false positive, it could lead a
patient to undergo prophylactic surgery, chemopreven-
tion, intensive screening, or other morbidity-inducing ac-
tions, while a false negative could result in a failure to re-
cognize an actual risk that may exist. Assessments for
drug responses carry the risks that patients relying on such
tests may begin to self-manage their treatments through
dose changes or even abandon certain therapies depen-
ding on the outcome of the assessment. For example, false
genotype results for your warfarin drug response test
could have significant unreasonable risk of illness, injury,
or death to the patient due to thrombosis or bleeding
events that occur from treatment with a drug at a dose
that does not provide the appropriately calibrated antico-
agulant effect. These risks are typically mitigated by In-
ternational Normalized Ratio (INR) management under a
physician’s care. The risk of serious injury or death is
known to be high when patients are either non-compli-
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over, questions were raised whether about the commer-
cial nature of the information and potential overstatements
of the utility of the tests. In its statement, the European
Society of Human Genetics wrote the following: “Research
on DTC advertising of prescription medicine has shown
that this has created an inappropriate demand for medi-
cations. Moreover, it has shown that various advertise-
ments for drugs have been misleading. Overstatement of
effectiveness or minimization of risk has led to inade-
quate or inappropriate changes in medication, diet or
lifestyle by consumers. DTC advertising of genetic tests
for health-related purposes runs the same risks as DTC
advertising of prescription medicine in this regard. Ag-
gressive marketing strategies and slogans for DTC gene-
tic testing might overstate the potential for predictive
information of such tests and overrate its future health
implications. All this is likely done to increase test uptake
and artificially create new demands, that is, to earn mo-
ney. We strongly believe that every advertisement should
conform to the same international standards and guide-
lines that apply for advertisement of drugs and medical
devices. Among other issues, the advertisement should
be accurate and not misleading, claims should be trans-
parent and supported by current evidence, and complete
and accurate information about the test limitations, risks
and benefits should be provided.”(6)
With regard to genetic counselling, various commenta-
tors have criticized the lack of involvement in DTC gene-
tic testing of an appropriately trained person to help the
individual or the family to understand the medical facts
of the disorder and the options on how to deal with it. In
the cases that genetic counselors were involved, criti-
ques were rather focused on the potential conflict of in-
terest that may arise when the healthcare professionals
involved in the counseling are employed by or linked to
the companies selling the tests. In this case impartial
health advice might be compromised. Concerns were
also raised with regard to the reduction of the informed
consent process to signing a test order or clicking a box.
(6) Moreover, since biological samples are taking in the
privacy of someone’s home, there is no way of control-
ling for the identity of the sample provider. Testing of third
parties without adequate consent becomes possible and
rather impossible to control.
Absence of individualized medical supervision
In a review of policy guidelines and position papers on
DTC genetic testing, Skirton et al. showed that “strong
recommendations were made about the need to involve
trained and quali_ed health professionals to provide both
accurate information and pre- and post-test counselling.”
This is a particular concern as many DTC genetic testing
companies operate without the supervision of a qualified
health professional. Whether or not this should be a
physician is not specified in every document. (31) The
European Society of Human Genetics mentioned that the
“offer of genetic tests providing health-related informa-
tion, in the absence of clinical indications and individuali-
zed medical supervision, may compromise patient health.
Key concerns are the provision of sufficient information
about the purpose and appropriateness of testing, its
possibilities and limitations, as well as the clinical signifi-
cance of testing. An involvement of independent medical
professionals could avoid the waste of money on tests
that are clinically irrelevant. In addition, the cost and ad-
verse psychosocial effects of unnecessary follow-up or me-
dical investigations could be avoided.” (6) The mere in-
volvement of a physician in this process might not re-
solve all the concerns with regard to DTC genetic testing,
as concerns with regard to the clinical validity or clinical
utility of tests might remain. 
ant or not properly dosed; combined with the risk that a
direct-to-consumer test result may be used by a patient to
self-manage, serious concerns are raised if test results are
not adequately understood by patients or if incorrect test
results are reported.”
Potential negative psychological impact
Concerns were raised that consumers might misinterpret
genetic test results or might experience psychological
distress caused by abnormal test results. Consumers who
obtain a test result that reveals an increased risk for a cer-
tain condition may over-estimate the risk they have of
developing disease and this may cause undue stress and
anxiety and unnecessary follow-up tests or treatments. In
contrast, consumers with results that suggest standard or
inferior than average risk of developing a disorder may
understand this as meaning that they no longer have to
worry about leading a healthy life style. (27;28) 
Some studies have analyzed the psychological impact of
consumers receiving risk profiles for common complex
disorders. Bloss et al. reported that in a selected sample
of subjects who completed follow-up after undergoing
consumer genomewide testing, such testing did not re-
sult in any measurable short-term changes in psychologi-
cal health, diet or exercise behavior, or use of screening
tests. As the study was peformed within a self-selected
group, the authors didn’t make any claims about the po-
tential effect of this type of genetic testing on the popula-
tion at large. (29) In a more recent study, Bloss et al. re-
ported about the long term psychological, behavioural
and clinical impacts of genomic risk testing for common
diseases. The researchers concluded that genomic testing
was not associated with long term psychological risks. (30)
These studies indicate that concerns about a negative psy-
chological impact of DTC genetic testing on individuals
who obtained such testing might be exaggerated. Never-
theless, as the mentioned studies were limited due to a
self-selected group and the focus on genomic risk testing
for common diseases, it might not be representative for
the whole population, neither for other types of tests, such
as targeted, exome or whole genome sequencing.
Absence of pre- 
and post-test counseling 
and of an adequate informed consent
In a review of policy guidelines and position papers on
DTC genetic testing, Skirton et al. showed that “all docu-
ments in the review considered the potential for harm
due to lack of understanding or information about the
test, and particular recommendations focussed on infor-
mation that should be available to consumers.” (31) In par-
ticular, Skirton et al reported the importance of various
types of information (and related issues) when offering a
test: the purpose and nature of the test, the risks associa-
ted with testing, accurate information on clinical utility,
the scientific evidence supporting the use of the test (in-
cluding validity), the availability of counselling by a health
professional, the availability of treatment or lack of treat-
ment for the condition, the format and presentation of
the results, the implications of the results, the quality regu-
lation of the laboratory, the management and care of the
sample, the confidentiality of results and security of samp-
les, the subsequent use or storage of samples, sources of
independent information, possible impact on insurance
or employment. 
The fact that many companies only have written informa-
tion on their website and don’t allow for pre-test face to
face information has been a matter of concern. More-
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Potential burden on the healthcare system
Although the actual impact of DTC genetic testing on
public healthcare systems remains largely understudied,
several studies have indicated that consumers would con-
tact or have contacted healthcare professionals. A British
study reported that 78% of the study participants would
consult a healthcare professional on their test result. (32)
Another study found that 86.9% of the general public
would seek more information about test results from
their doctor. (33) The degree to which these stated in-
tentions translate into actual physician visits is unclear.
Another study showed that 53% of those who had used a
test had visited their physicians regarding the results and
10% planned to do it. (34) As commented earlier “for
health systems striving to contain costs, even a small in-
flux in use is a potential health policy issue, particularly
given the questionable clinical utility of the tests offered
by DTC companies.” (35)
Other concerns
Other concerns with regard to the activities of DTC com-
panies include the research activities of these companies
performed on submitted samples and information without
adequate informed consent or monitoring by a research
ethics committee (36). In addition, concerns were raised
about what is happening to the samples and data when a
company is going bankrupt (37). Moreover, when looking
at the policies of DTC genetic testing companies, it is clear
that various companies are testing minors which is in op-
position to clinical guidelines. (38; 39)
Policy strategies
In the following part of the article we will discuss some
policy strategies that have been implemented or sugges-
ted, and that might impact DTC genetic testing services.
In particular, we will focus here on 1) education for the
general public and health care professionals, 2) initia-
tives for self-regulation, 3) the call for implementing
information and advertising standards, 4) the provision
of genetic tests through medical doctors, 5) the penali-
zation of users, or 6) the sanctioning of non-consensual
testing. We will not expand on this in this article, but it is
worth mentioning that some proposals were also made
to have quality labels for DTC genetic testing. In the
Netherlands, a permit system exists that has an impact on
the provision of DTC genetic testing. (40)
Education for the general public 
and health care professionals
Various policy documents have mentioned the need to
inform the general public and health care professionals
about the limitations of DTC genetic testing. (31) A re-
port of the Belgian Superior Health Council for example
emphasized the importance of information provision: “In
light of growing number of companies selling and adver-
tising genetic tests DTC, the Superior Health Council
considers that it is crucial that information is available
for healthcare professionals and the general public that
gives background on genetic testing and describes the
provision of genetic testing services. On one hand, it is
important to underline that clinically validated and medi-
cally appropriate genetic tests are offered in clinical ser-
vices for those that need them and that these are reim-
bursed by the healthcare system. On the other hand, it is
important that information is available about the limita-
tions and concerns of the tests that are currently adver-
tised, provided or sold through the internet.”
Also the Nuffield Council of Bioethics recommended
“that appropriate publicly-funded health service websites
should include general information for the public about
direct-to-consumer genetic profiling services provided
by commercial companies. This information should in-
clude reference to: potential risks and benefits; any diffi-
culties with establishing clinical validity; the possibility
of finding out about conditions for which treatment is
not available; the special case of children; and whether it
could be necessary for consumers to inform life, mort-
gage or travel insurance companies of the results of any
tests, either at the time or in the future. We further recom-
mend that governments should require details about whe-
re to find this information to be included in the advertising
and information provided by companies selling genetic
profiling services in their countries.” (41)
Over the past years, various leaflets providing informa-
tion on DTC genetic tests were developed. (42;43) A de-
cision support tool for health professionals was also de-
veloped. (44)
Encouraging industry self-regulation
The Human Genetics Commission of the UK took impor-
tant initiatives in order to set standards and principles
with regard to DTC genetic testing and to promote their
consistent use at an international level. In a document
(4), it developed a common framework of principles for
DTC genetic testing services with attention to standards
with regard to marketing and advertising, information for
prospective consumers, counselling and support, consent,
data protection, handling of the samples, laboratory pro-
cesses, interpretation of the results, provision of the re-
sults and procedures to tackle complaints. In its princip-
le 1.1., the Human Genetics Commission made clear that
the goal of those principles were to ensure “good prac-
tice” and to safeguard the interests of the consumer. Although
praised for its intention, this common framework was
also criticized. In a public reaction during the consulta-
tion phase of the document of the Human Genetis Com-
mission, the Professional and Public Policy Committee of
the European Society of Human Genetics, for example, sta-
ted that the “guiding principles focus too much on the
requirements the test providers should fulfill while pay-
ing too little attention to the quality of the genetic tests
that are being sold. The PPPC remains concerned about
the quality of the tests provided and believes that the
clinical validity (and not only the analytical validity) of
genetic tests should be proven before one can even be-
gin to consider selling such tests directly-to-consumers.”
(45) Moreover, the PPPC advanced that the Principles
reduced “reduce the informed consent process to a pro-
cess in which the test providers have to provide sufficient
and appropriate information” and that “the current Prin-
ciples do not put enough responsibility on the test pro-
viders to ensure that the consumers comprehend the dis-
closed information, act voluntarily, and are competent to
act and consents to all elements of the consent form. Pro-
viding information does not substitute obtaining infor-
med consent.” (45) Although the common framework
was developed in dialogue with representatives of the
DTC genetic testing industry, the impact of the common
framework on this industry remained limited.
Implementation of transparent information
and advertising standards
Various policy documents have mentioned the impor-
tance of adequate and correct information provision. The
European Society of Human Genetic, for example, has sta-
ted that “labelling information on genetic tests must be
true, accurate, accessible, complete and comprehensible.
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Although some companies have websites providing most
or all of this, the information is often of promotional na-
ture and intended to sell tests, which might compromise
the truth in labelling.” (6) 
Regulation of genetic tests
In the European Union, genetic tests are currently regu-
lated by the Directive 98/79/EC on in vitro diagnostic
(IVD) medical devices. This Directive was adopted in or-
der to facilitate within the European Union an internal
market for IVD medical devices and in order to make
sure that such devices meet essential requirements at the
level of safety and performance before market introduc-
tion. This Directive was criticized in the past among other
issues for its list-based classification system lacking con-
sistency and which required for most genetic testing on-
ly a self-certification prior to market introduction. As we
explained earlier, “On September 2012, the European
Commission presented a proposal for a new legal instru-
ment after several years of public consultations. Instead
of a Directive, this instrument would be a Regulation
which means that this piece of legislation will be imme-
diately binding for all Member states without a transposi-
tion into national law being necessary (European Union).”
(46) The European parliament amended the proposed
version of the European Commission and introduced va-
rious articles which may affect the DTC genetic testing
market. The voted version of the European Parliament is
currently being considered by the Council of the Euro-
pean Union. (47) This proposed Regulation contains a
the risk-based classification of IVD medical devices, which
makes of genetic tests Class C devices making premarket
review by a Notified Body necessary. Amendment 72 fo-
resees that all health-related genetic testing may only be
ordered by “persons admitted to the medical profession
under the applicable national legislation after a personal
consultation.” (48) The same amendment also provides
the obligation to provide the test applicant “with appro-
priate information on the nature, the significance and the
implications of the genetic test.”(48) Furthermore, it un-
derlines the necessity of “appropriate genetic counsel-
ling” before the provision of a genetic test, and that “the
form and extent of this genetic counselling shall be de-
fined according to the implications of the results of the
test and their significance for the person or the members
of his or her family.”(48) Moreover, amendment 40 states
that “direct to consumer advertising of devices classed as
prescription only by this Regulation shall be illegal.” (48)
If approved, these provisions might heavily impact on the
provision of DTC genetic testing. 
Canalization of genetic 
tests through health-care professionals
In the above mentioned Proposed IVD Regulation gene-
tic tests may only be ordered by persons admitted to the
medical profession. Already at this moment various Eu-
ropean countries foresee in their legislations that genetic
tests should be ordered by physicians. This is for examp-
le the case in Germany where the German Bundestag pas-
sed on 24 April 2009 the Human Genetic Examination
Act (The Genetic Diagnosis Act, GenDG), which covers
genetic testing services. According to sec. 7 para. 1 of the
Act, a diagnostic genetic examination may only be under-
taken by physicians and a predictive genetic examination
may only be undertaken by medical specialists in the field
of human genetics or other physicians who have quali-
fied themselves via the acquisition of some specialist de-
signation for genetic examination within their specialist
area. Para. 2 states that the genetic analysis of a biological
sample may only be carried out within the scope of a ge-
netic examination and by the medical person in charge
or by person or institution commissioned by the respon-
sible medical doctor. Para. 3 finally declares that genetic
counseling according to sec. 10 may only be undertaken
by physicians named in para. 1 and who are qualified to
provide genetic counseling.”(40)  Also countries such as
Portugal and France have legislation that foresees the
provision of genetic tests through medical doctors. (40)
It should however be mentioned that the provision of ge-
netic tests through medical professionals is not a guaran-
tee that adequate genetic counseling is being provided
and that the clinical utility of genetic tests is guaranteed.
Penalization of users
In France, the French Law (Article 16-1 Civil Code) has
advanced that genetic tests can only be performed with a
medical prescription and by an authorised laboratory.
We described the French regulation in detail in another
publication. (49) The French law on Bioethics of 2011
integrated also an article that regulates the use of DTC
genetic testing by consumers. (50) Anyone who is reques-
ting a genetic test for him or herself, or for a third per-
son, or for identification through a DNA profile, outside
the conditions laid out by the law is punishable under
the article 226-28-A of the criminal code by a fine of
3750 euro. We have discussed this article in detail in a
previous article. “Although it is certainly defensible to
elaborate such a provision in the law in order to avoid
that the DNA of third parties be analyzed without their
consent or that paternity testing be done without con-
sent, it is questionable whether it is desirable that such a
provision should be elaborated for prohibiting access to
personal health information. The adoption of such a pro-
vision by the French legislator constitutes a serious in-
fringement to the principle of freedom, in the name of
protecting personal rights. This does not imply that per-
sonal freedom is an absolute right. The right to know
must be exercised with due respect for the necessary pro-
tection of individuals. The issue of DTC genetic testing
should be viewed in the general context of regulating a
freedom to access, and limitation of this access, if there
are doubts about the quality of the knowledge provided
by these companies or if there might be risks of harmful
effects for the person concerned or for public health. A
regulation focusing on the prohibition of use of DTC ge-
netic testing by consumers aims to emphasize the res-
ponsibility of individuals. In an age of internet access to
genetic testing on an international scale, it also provides
a warning to individuals not to order genetic tests. How-
ever, in addition to enforcement problems of such a regu-
lation, arguments coming from the protection of Public
Health are more convincing if a legislator aims to regu-
late DTC genetic testing. From this perspective, the French
Bioethics law, which reinforces the conditions to be ful-
filled for the provision of genetic testing, did not require
legislation that also restricts individual freedom to obtain
personal information.”(50)
Penalization of non-consensual testing
Non-consensual genetic testing involves the collection of
biological materials of a third person with the intention
to do a DNA analysis without obtaining consent. Biologi-
cal materials needed for a genetic testing can be obtai-
ned through discarded tissues, used coffee cups and smo-
ked cigarettes left behind.(51) It has been shown that so-
me DTC companies are not unwilling to process samples
that are being submitted without proper consent. (52)
Cases of ‘DNA theft’ and ‘genetic stalking’ were also
reported in the literature and media. (53-57) It was re-
ne. Direct-to-consumer genetic testing for health-related purpos-
es in the European Union. 2012. http://www.easac.eu/filead-
min/Reports/EASAC_Genetic_Testing_Web_complete.pdf
Accessed 7 April 2013. Ref Type: Report (17) Haddow J, Paloma-
ki G. ACCE: a model process for evaluating data on emerging ge-
netic tests. In: Khoury MJ, Little J, Burke W, editors. Human Ge-
nome Epidemiology: a scientific foundation for using genetic in-
formation to improve health and prevent disease. New York:
Oxford University Press; 2003. (18) Grosse SD, Khoury MJ. What
is the clinical utility of genetic testing? Genet. Med.2006; (8):
448-450. (19) Mihaescu R, van Hoek M, Sijbrands EJG, Uitterlin-
den AG, Witteman J, Hofman A et al. Evaluation of risk prediction
updates from commercial genome-wide scans. Genet. Med. 2009;
11(8):588. (20) Janssens ACJW, van Duijn CM. An epidemiological
perspective on the future of direct-to-consumer personal geno-
me testing. Investigative Genetics 2010; 1(1):1-5. (21) Janssens
ACJW, Wilde AAM, van Langen IM. The sense and nonsense of di-
rect-to-consumer genetic testing for cardiovascular disease. Nether-
lands Heart Journal:1-4. (22) Mihaescu R, Meigs J, Sijbrands E,
Janssens C. Genetic risk profiling for prediction of type 2 diabe-
tes. PLoS Currents 3. (23) Palomaki GE, Melillo S, Neveux L, Doug-
las MP, Dotson WD, Janssens A et al. Use of genomic profiling to
assess risk for cardiovascular disease and identify individualized
prevention strategies. A targeted evidence-based review. Genet. Med.
2010; 12(12):772. (24) Janssens AC, Gwinn M, Bradley LA, Oost-
ra BA, van Duijn CM, Khoury MJ. A critical appraisal of the scien-
tific basis of commercial genomic profiles used to assess health
risks and personalize health interventions. Am J Hum Genet
2008; 82(3):593-599. (25) Kutz G. Nutrigenetic testing. Tests
purchases from four web sites mislead consumers. Washington:
United States Government Accountability Office; 2006. (26) Pub-
lic Health Service Food and Drug Administration. 2014. http:/
/www.fda.gov/iceci/enforcementactions/warningletters/2013/u
cm376296.htm Accessed 1 April 2014. Ref Type: Online Source
(27) McBride CM, Koehly LM, Sanderson SC, Kaphingst KA. The
behavioral response to personalized genetic information: will
genetic risk profiles motivate individuals and families to choose
more healthful behaviors? Annu Rev Public Health 2010; 31:89-
103. (28) McBride CM, Wade CH, Kaphingst KA. Consumers' Views
of Direct-to-Consumer Genetic Information. Annu Rev Genomics
Hum Genet 2010. (29) Bloss CS, Schork NJ, Topol EJ. Effect of
direct-to-consumer genomewide profiling to assess disease risk.
N Engl J Med 2011; 364(6):524-534. (30) Bloss CS, Wineinger NE,
Darst BF, Schork NJ, Topol EJ. Impact of direct-to-consumer geno-
mic testing at long term follow-up. J Med Genet 2013; 50(6):393-
400. (31) Skirton H, Goldsmith L, Jackson L, O'Connor A. Direct
to consumer genetic testing: a systematic review of position sta-
tements, policies and recommendations. Clin. Genet. 2012. (32)
Cherkas LF, Harris JM, Levinson E, Spector TD, Prainsack B. A sur-
vey of UK public interest in internet-based personal genome tes-
ting. PLoS One 2010; 5(10):e13473. (33) Leighton JW, Valverde
K, Bernhardt BA. The general public's understanding and percep-
tion of direct-to-consumer genetic test results. Public Health Ge-
nomics 2012; 15(1):11-21. (34) McGuire A, Diaz CM, Wang T, Hil-
senbeck S. Social Networkers' Attitudes Toward Direct-to-Con-
sumer Personal Genome Testing. Am. J. Bioethics 2009; 9(6-7):3-10.
(35) Caulfield T, Borry P. Direct-to-consumer genetic testing - whe-
re should we focus the policy debate? Med. J. Aust. 2013; 198(9)
:499-500. (36) Howard HC, Knoppers BM, Borry P. Blurring li-
nes. The research activities of direct-to-consumer genetic testing
companies raise questions about consumers as research subjects.
EMBO Rep 2010; 11(8):579-582. (37) Zawati MH, Borry P, Howard
HC. Closure of Population Biobanks and Direct-to-Consumer Gene-
tic Testing Companies. Human Genetics 2011; in press. (38) Bor-
ry P, Howard HC, Senecal K, Avard D. Health-related direct-to-con-
sumer genetic testing: a review of companies' policies with re-
gard to genetic testing in minors. Fam. Cancer 2009; 9(1):51-59.
(39) Borry P, Howard HC, Senecal K, Avard D. Direct-to-consu-
mer genome scanning services. Also for children? Nat. Rev. Genet.
2009; 10(1):8. (40) Borry P, van Hellemondt RE, Sprumont D, Ja-
les CF, Rial-Sebbag E, Spranger TM et al. Legislation on direct-to-
consumer genetic testing in seven European countries. Eur J Hum
Genet 2012; 20(7):715-721. (41) Nuffield Council on Bioethics.
Medical profiling and online medicine: the ethics of 'persona-
lised healthcare' in a consumer age. Oxfordshire: Nuffield Press;
2010. (42) Genetic Interest Group. Over-the-counter Genetic Sus-
ceptibility Tests. Information for individuals, families and non-
specialist health professionals. http://www.geneticalliance.org.
uk/docs/OTCbooklet09.pdf: 2009. (43) Federal Trade Commis-
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ported earlier that “Thwarting surreptitious genomic tes-
ting may require new laws to protect privacy by making
it a crime to possess someone else’s DNA with the intent
to analyze it without consent.”(58) In the UK, the Human
Tissue Act included specific provisions that makes the
procurement of some else’s biological sample for DNA
analysis without their knowledge a legal offence.(49)
Conclusion
Direct-to-consumer genetic testing has been heavily de-
bated over the last years. Various professional societies
and governmental bodies have issued policy statements
discussing various concerns, risks and limitations. Policy
reactions, however, vary. While some emphasize the im-
portance of self-regulation of this industry and focus on
some minimum criteria related to the provision of those
services (transparency, truth in labelling…), others have
emphasized the importance of genetic counselling and
medical supervision, as well as premarket assessment of
genetic tests. With the increasing amount of genetic in-
formation that can be generated at a decreasing costs, a ma-
jor challenge will be how to make innovative tests acces-
sible in diagnostics and screening, while avoiding un-
sound applications.(59)
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Abstract*
The paper aims to provide an overview of the most im-
portant concerns related to direct-to-consumer genetic
testing and of the regulatory approaches that have been
presented and/or implemented. Direct-to-consumer gene-
tic testing has been heavily debated over the last years.
Various professional societies and governmental bodies ha-
ve issued policy statements discussing various concerns,
risks and limitations. Policy reactions, however, vary. Whi-
le some emphasize the importance of self-regulation of
the industry and focus on some minimum criteria related
to the provision of those services (transparency, truth in la-
belling etc.), others have emphasized the importance of
genetic counselling and medical supervision, as well as
premarket assessment of genetic tests. With the increa-
sing amount of genetic information that can be genera-
ted at a decreasing costs, a major challenge will be how
to make innovative tests accessible in diagnostics and scree-
ning, while avoiding unsound applications. 
Key words: genetic tests, internet, direct-to-consumer ad-
vertising and selling, risks, limitations, regulatory policies
Abstrakt*
Práca prináša prehľad najvýznamnejších výhrad voči ge-
netickým testom, ktoré sa poskytujú priamo zákazníkovi,
ako aj prehľad regulačných prístupov, ktoré sa navrhli ale-
bo implementovali. Genetické testy poskytované priamo
zákazníkovi sa v posledných rokoch široko debatovali.
Rôzne odborné spoločnosti a štátne orgány publikovali sta-
noviská venované rôznym výhradám, rizikám a limitáciám
týchto testov. Na úrovni konkrétnych opatrení sa však
prístupy značne líšia. Kým niektoré zdôrazňujú význam
samoregulácie samotných výrobcov testov a sústreďujú sa
na minimálne kritériá pri poskytovaní takýchto služieb
(transparentnosť, pravdivé označovanie atď.), iné zdôraz-
ňujú význam genetického poradenstva a lekárskeho do-
hľadu, ako aj predmarketingového hodnotenia genetic-
kých testov. So vzrastajúcim množstvom genetických in-
formácií, ktoré je možné generovať pri klesajúcich cenách
týchto vyšetrení, zásadným problémom ostáva ako zabez-
pečiť na jednej strane dostupnosť inovatívnych testov v
diagnostike a skríningu a zároveň sa vyhnúť ich nezmy-
selnému používaniu. 
Kľúčové slová: genetické testy, internet, priama reklama
a predaj zákazníkom, riziká, obmedzenia, predpisy
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–
Article 7 – Individualised supervision
1 A genetic test for health purposes may only be per-
formed under individualised medical supervision.
2 Exceptions to the general rule referred to in para-
graph 1 may be allowed by a Party, subject to appropria-
te measures being provided, taking into account the
way the test will be carried out, to give effect to the other
provisions of this Protocol.
However, such an exception may not be made with regard
to genetic tests with important implications for the health
of the persons concerned or members of their family or with
important implications concerning procreation choices.
Article 8 – Information and genetic counselling
1 When a genetic test is envisaged, the person concer-
ned shall be provided with prior appropriate informa-
tion in particular on the purpose and the nature of the
test, as well as the implications of its results.
2 For predictive genetic tests as referred to in Article
12 of the Convention on Human Rights and Biomedici-
ne, appropriate genetic counselling shall also be availab-
le for the person concerned.
The tests concerned are:
– tests predictive of a monogenic disease,
– tests serving to detect a genetic predisposition or ge-
netic susceptibility to a disease,
– tests serving to identify the subject as a healthy car-
rier of a gene responsible for a disease.
The form and extent of this genetic counselling shall be
defined according to the implications of the results of
the test and their significance for the person or the
members of his or her family, including possible impli-
cations concerning procreation choices.
Genetic counselling shall be given in a non-directive
manner.
Additional Protocol to the Convention on Human Rights and Biomedi-
cine, concerning Genetic Testing for Health Purposes (2008)
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ETHICS OF PREVENTIVE MEDICINE
Focus on the Genetic Tests
Inge Liebaers
Center for Medical Genetics, UZbrussel, 
Vrije Universiteit Brussel, Belgium
Definition
General Preventive Medicine focuses on the health of indi-
viduals, communities, and defined populations, as defi-
ned by the American College of Preventive Medicine. Its
goal is to protect, promote, and maintain health and well-
being and to prevent disease, disability, and death. The
American College also states that in the context of public
health, general preventive medicine focuses on promo-
ting health, preventing disease, and managing the health
of communities and defined populations. The practitioners
combine population-based public health skills with know-
ledge of primary, secondary, and tertiary prevention-orien-
ted clinical practice in a wide variety of settings. 
A simpler definition, taken from the Merriam-Webster dic-
tionary, says that preventive medicine is a branch of medi-
cal science dealing with methods (as vaccination) of pre-
venting the occurrence of disease. Adapted to the context
of this meeting it becomes: ’A branch of medical science
dealing with methods – as genetic testing or genetic scree-
ning – of preventing disease at the individual or popula-
tion level’.
Genetic tests
Genetic tests are procedures which directly or indirectly
analyse the genome. The results can directly point to a
mutation causing a disease or they can indirectly diag-
nose a condition by measuring the activity of a gene pro-
duct like an enzyme or a metabolite not being processed
because of a missing enzyme. With increasing knowledge
and progress in technology, genetic tests are becoming
more and more powerful in exploring our genome. Using
them for individual or public health purposes, their ana-
lytical validity, clinical validity and utility as well as ethi-
cal, legal and socio-economical aspects should be taken
into account. (Hastings et al. 2012, Bowdin et al. 2014)
The new genetic tests
New genetic tests are micro-array analyses to detect
CNV’s (copy number variants) or SNP’s (single nucleoti-
de polymorphisms) and NGS (new generation sequencing)
techniques allowing WGS (whole genome sequencing)
or WES (whole exome sequencing). NIPT (non-invasive
prenatal testing) uses also the NGS technology. Microar-
ray analysis allows to find out if the cause of multiple
congenital abnormalities in a person are due to a dele-
tion or duplication of a piece of DNA. Sequencing techni-
ques allow to find gene mutations. NIPT is a performant
screening test for trisomy 21 during pregnancy (Katsanis
and Katsanis, 2013).
Testing versus screening
Genetic testing is requested and performed in the con-
text of a personal or familial medical problem. Testing
can occur postnatally or prenatally. The reason for the
testing is to find an answer to a medical question (Sequei-
ros  et al., 2011). The following example illustrates the dif-
ferent possibilities. 
(1) A boy as well as his brother and maternal uncle pre-
sent with a developmental delay. An X-linked fragile X
syndrome is suspected. Molecular analysis of the FMR1
gene confirms the diagnosis by finding an expanded CGG
repeat. The mother of the boys must be a carrier and in-
deed a premutation is found in the same gene. If the sis-
ter of the mother or the sister of the boys wants to know
if they are carrier, they can ask to be tested. Knowing,
whether they are carrier or not, is important in view of
reproduction. Within the frame of genetic counseling,
recurrence risks can be given and prenatal diagnosis
(PND) or pre-implantation genetic diagnosis (PGD) for
the condition can be discussed and performed. (Saul and
Tarleton, 2012) 
(2) Another example relates to pre-symptomatic testing
for dominant late onset conditions like Huntingtons dis-
ease. A person, whose father or mother has the condi-
tion, has a 50 % risk of inheriting the causal mutation and
develop the disease after his or her reproductive age.
They may want to know in order to discuss about their
reproductive choices. A pre-symptomatic test can be ob-
tained in accordance with international guidelines. The
information may be important to him or her in view of
reproduction (de Die-Smulders et al, 2013). 
(3) The method of choice to day to explore/find the cau-
se of multiple malformations and mental dysfunction in a
child or a foetus is CNV-micro-array. Again when a diag-
nosis is made, information can be given to the patient or
the parents and choices can be made (Peters and Pertile,
2014). 
(4) For problems such as deafness or retinitis pigmento-
sa, next generation sequencing can be used to find the
causal mutation (Vona  et al. 2014).
Genetic screening is offered in the context of a possible
risk or problem in a healthy population. Genetic scree-
ning can occur postnatally or prenatally. 
(1) Neonatal screening is a variably established procedu-
re generally based on metabolite or gene-product analy-
sis and not yet on direct gene-testing. The aim is to be
able to treat as soon as possible. Genetic counseling can
follow later. Screening programmes based on new genetic
sequencing technologies can be envisaged. The next step
could be to store the sequence ‘somewhere’ and interro-
gate/analyse this sequence whenever a health problem of
that person has to be answered or when screening like
for breast cancer mutations may seem appropriate. (Cor-
nel et al. 2011, Loeber et al, 2012, Bowen et al.2012). 
(2) Carrier screening based on mutation analysis for au-
tosomal recessive conditions occurs in certain populations
like Ashkenazi Jews, who are tested for Tay-Sachs disease
among other specific diseases, or inhabitants of regions
like Cyprus and Sicily who are tested for thalassemia be-
cause these diseases are more prevalent (Schneider et al,
2009). Testing for carriership of cystic fibrosis in high in-
cidence populations is not yet generalized. The aim of
these screening programmes is to allow couples to make
reproductive choices. Screening-panels for over 300 re-
cessive conditions do now exist and are made available by
direct to consumer testing companies like Counsyl. Why
not, may be the question. In any case, admitting that the
analytical validity of these tests is correct, its clinical vali-
dity and its clinical utility remain to be demonstrated. 
(3) Based on new genetic testing possibilities, direct to
consumer screening tests for complex conditions based
on incomplete research data have been offered by com-
panies. Unacceptable as far as I am concerned because
not yet ready for private or public health purposes. (van
El and Cornel, 2011)
Prenatal screening during pregnancy can be invasive and
specific such as testing the fetus for trisomy 21 by chorio-
nic villus sampling or amniocentesis. Its clinical applica-
tion has over the years evolved from offering it to preg-
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nant women over 35 years of age to women of all ages
but at increased risk based on prior non-invasive com-
bined testing (nuchal translucency and maternal serum
analysis). Today the ‘non invasive prenatal test’ or NIPT is
increasingly proposed as a secondary (after the com-
bined test) or primary  screening test for trisomy 21, 18
and (13) (with high sensitivity and specificity) to preg-
nant women. If the result points to trisomy 21, still an
invasive test will be performed before any termination.
The question is whether with time, the NIPT may be-
come a diagnostic test at least for trisomies. (Bianchi, et
al, 2014)
In the meantime prenatal diagnosis by NIPT of some
monogenic conditions has been performed. Recently the
possibility of WGS by NIPT has been published (Yurkie-
wicz et al.2014). Prenatal screening for chromosomal
aneuploidy before pregnancy that is to say, oocyte or emb-
ryo screening within the frame of assisted reproduction
has been and is being offered and performed. Such pre-
implantation genetic screening or PGS based on counting
certain chromosomes like 21, 18, 13 using fluorescent in
situ hybridization (FISH) has been performed with more
or less success. Limited published results, based on the
micro-array technology, allowing the counting of all chro-
mosome pairs at the blastocyst stage (day 5 after insemi-
nation) instead of the cleavage stage (day 3) claim to
improve success rates in in vitro fertilization by selecting
euploid embryos for transfer. (Scott et al. 2013). If not
yet practically, theoretically WGS of preimplantation
embryos is close by. The question is, whether to do it, when
technically possible and reliable. If yes, the next question
is how to choose the best embryo for the transfer? (Wi-
nand et al, 2014)
Ethics and genetic tests
Genetic tests tend to be more controversial than other
medical tests although it is not always clear why.  
One of the reasons is probably the fact that the result of a
test may disclose a condition of another family member
or may increase the risk of other family members to be at
risk. One example is the presymptomatic testing for
Huntington’s disease and now also other late onset con-
ditions within a family. Imagine that a grand daughter of
an affected person wants to know her status but her mo-
ther doesn’t want to know. If she is carrier of the disease
causing mutation, her mother has to be a carrier as well.
Another example is carrier testing for recessive condi-
tion at the individual or population level. If a person
finds out he is carrier, the risk of his family members to
be carrier as well increases. 
Another reason why genetic tests may be controversial
has to do with the risk that genetic information me be
misused by insurance companies or employers. With the
new technologies, such as micro-array analysis, whole
genome, or exome sequencing, new problems or chal-
lenges arise related to the unsolicited or incidental fin-
dings also called secondary medically actionable variants
(MAV’s) and yet variants of unknown significance (VUS)
(Bowdin et al. 2014). Discussions and clinical research
projects are ongoing in order to learn how to deal with
these new problems (Kullo et al 2014; Jarvik et al. 2014).
Ethical questions concerning genetic testing
If postnatal testing is performed within a family because
of an existing problem in a child or an adult and a causal
abnormality is found allowing to establish a diagnosis,
the consequence may be that other family members are
at risk to have the same condition or to have an increased
risk to have affected offspring. Therefore, the family mem-
bers at risk should be informed. Is this mandatory? What
if the patient does not want to inform his or her family?
Can or should the physician try to contact the family. The
principles of beneficence, non-malficence, autonomy ha-
ve to be taken into account. Sometimes the duty to in-
form may have to overrule privacy matters. Prenatal tes-
ting within a family should be a personal decision, be it du-
ring pregnancy or before pregnancy. Unfortunately, be-
cause of legal aspects and financial aspects which differ
in countries, the availability of prenatal diagnostic proce-
dures and preimplantation genetic diagnostic procedu-
res are not equally available. With the technologies such
as micro-array, the problem of unsolicited findings or the
findings of unknown significance have arisen. In Belgium,
the Centers for Medical Genetics use a consensus model, to
be evaluated at regular intervals, as to how to handle the
problem (Van Akker et al, 2013).
Questions to be asked concerning postnatal screening
are numerous. Screening for recessive conditions is pos-
sible today and the number of diseases for which scree-
ning will be possible is increasing. Questions are related
to which diseases to test for, who should offer testing,
and who should pay? The discussion here is maybe more
socio-economical than ethical. But how to handle genetic
screening for late onset dominant conditions and com-
plex diseases? Certainly in Europe, professionals in gene-
ral are not in favor of offering these tests at the moment,
but companies do or at least did. (Annas and Elias, 2014).
If such tests are performed on demand by companies,
tested persons may or will turn to professionals, who
have to explain the meaning of the results and solve pos-
sible problems. 
Questions concerning prenatal screening have always
existed in the ethical debate and will remain. The main
aim in screening programmes today is directed towards
trisomy 21 and other less frequent non-lethal trisomies,
as well as towards morphological abnormalities. Techno-
logy is available and improving, again not in an equitable
way throughout Europe, unfortunately. Taking into account
the analytical validity, as well as the clinical validity and
utility of the NIPT, invasive prenatal screening is no lon-
ger the standard procedure. Non-invasive screening is in-
deed the way to go with NIPT as a secondary or even pri-
mary screening procedure next to ultrasound imaging.
However, NIPT with WGS is on its way. (Yurkiewicz et al.
2014) Here a broad multidisciplinary discussion at seve-
ral levels seems mandatory before application. Concer-
ning pre-implantation screening (PGS), a difference exists
between the USA and Europe. In the USA, PGS, now ba-
sed on micro-array analysis, is offered to all IVF patients
in some centers for reproductive medicine. They claim
that IVF results improve by selecting the best possible
embryo for transfer and at the same time decrease the
miscarriage rates and the risk of the birth of a child with
a chromosomal anomaly like trisomy 21. (Scott et al.
2013). These claims have still to be confirmed by proper
studies. The next question will be concerning WGS of
the embryos. Based on what is known today, I am afraid
that no embryos will be left for transfer (Winand et al.
2014). If this is correct, it may be a reason to refrain from
using the technology at least in a clinical setting. When
used in a research setting we will learn a lot.
Pro’s and con’s of the new genetic tests
The new developments in genetic testing are, as said al-
ready, very valuable in research. Apart from finding more
causal small deletions or duplications responsible for
congenital anomalies as well as new genes and mutations
in rare mostly monogenic diseases, they allow to increase
the knowledge about the role of genetics in at least on-
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cology, complex diseases and pharmacology. In the clinic,
they are an added value if properly used for diagnostic
and counseling purposes. In other words their analytical
validity and clinical validity should have been evaluated
and their clinical utility proven.  The cost of these tests is
continuously decreasing making them more easily avai-
lable. At the moment the occurrence of unsollicited fin-
dings or MAV’s and the findings of unknown significance
or VUS are considered to be a burden. In the past it was
rather exceptional to have unclear test results and time
was needed to explain this to patients (Solomon, 2014).
With the new tests, we expect unsolicited findings and fin-
dings of unknown significance. It is imperative to decide
beforehand on the one hand which information will be
made available to the patient and on the other hand ask
the patient what they want to know. Next to the oral ex-
planations, a written informed consent seems mandatory
(Ormond, 2013). A way to limit unsollicited findings is
by targeting the tests as much as possible which is the
recommendation of the European Society of Human Ge-
netics. However, views may differ, as exemplified by the
American College of Medical Genetics, because their recom-
mendation says that if WGS is used to solve a given prob-
lem, another 56 chosen genes should be investigated (van
El et al. 2013, Green et al. 2013, Dorschner, et al. 2013). Com-
panies, mainly USA based, have taken advantage of the
new tests by offering  genomic screening for health pur-
poses based on research data still in progress. However,
because of constraints, their activities have recently gone
down or stopped altogether. (Annas and Elias, 2014)
Public health genomics
Many are convinced that the knowledge about our geno-
me and the technology allowing to explore our genome
better and faster will change medicine and public health.
The statement may be true but the changes occur more
slowly than originally thought. Maybe, it is better this
way in order to be able to learn from gradual implemen-
tation of new tests based on the new knowledge. Along
the same lines, one has to admit that except for some ex-
ceptions, personal medicine in general is still far away
because the genome is not the only player in public or in
the individual health.
Conclusion
In the field of human and medical genetics, times are ve-
ry exciting for researchers and clinicians. It is fair to say
that although knowledge and technology are explosive,
there is still a lot to learn. Most probably, gradual imple-
mentation of the new genetic tests in the clinic and in
society will allow us to cope. At the same time, we may
have to refrain from using technology simply because it
is available, without thinking, in a multidisciplinary man-
ner, about the possible consequences.
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Abstract*
The paper gives an overview of the most frequent practi-
cal and ethical issues with regard to the use of genetic
tests in the context of preventive medicine. Genetic tests
tend to be more controversial than other medical tests,
although it is not always clear why. One of the reasons is
probably the fact that the result of a test may disclose a
(still asymptomatic) condition in another family member
or may reveal his/her increased risk. Another reason
might be the supposed risk that genetic information may
be misused by insurance companies or by the employers,
or that it may result in other unjust discrimination or
stigmatization of the individual. Several actual scenarios
are discussed in the paper. With the novel methodologies
of laboratory investigation, the available knowledge on
genetic aspects of numerous human conditions and dis-
eases is increasing exponentially. There is still a lot to
learn, however. A gradual implementation of the new
genetic tests in the clinic and in society may provide
some time and mental space to cope with the over-
whelming quantities of generated data and multifaceted
knowledge. In the meantime, it seems important to
refrain from using the new powerful technologies sim-
ply because they are available, without thinking, in a mul-
tidisciplinary manner, about the possible consequences
of their hastened implementation. 
Key words: preventive medicine, genetic tests, predicta-
bility, clinical validity, clinical utility, ethics  
Abstrakt*
Práca poskytuje prehľad najčastejších praktických a etických
problémov vo vzťahu k využitiu genetických testov v kon-
texte preventívnej medicíny. Genetické testy sa môžu
javiť ako problematickejšie ako iné medicínske vyšetre-
nia, hoci nezriedka nie je dobre jasné, prečo. Jednou z
príčin môže byť skutočnosť, že výsledok testu môže
odhaliť (dosiaľ asymptomatické) ochorenie u iného člena
rodiny alebo upozorniť na jeho zvýšené riziko. Ďalšou
príčinou môže byť predpokladané riziko, že by získaná
genetická informácia mohla byť zneužitá zo strany pois-
ťovní a zamestnávateľov, alebo že by mohla viesť k nespra-
vodlivej diskrimáncii alebo stigmatizácii daného jed-
notlivca. Viaceré aktuálne možnosti sa podrobnejšie dis-
kutujú v práci. S príchodom nových metód laboratórnych
vyšetrení dostupné poznatky o genetických aspektoch mno-
hých ľudských chorôb a porúch narastajú exponenciál-
ne. Napriek tomu však ostáva ešte veľa nepoznaného. Pos-
tupné zavádzanie nových genetických testov do klinické-
ho a širšieho populačného použitia môže poskytnúť čas a
mentálny priestor, aby sa umožnilo lepšie zvládnutie ob-
rovského množstva generovaných údajov a mnohostranných
poznatkov. Medzičasom je veľmi dôležité, aby sa neponáh-
ľalo s použitím výkonných technológií iba preto, že sú dos-
tupné, bez predchádzajúceho interdisciplinárneho uvažo-
vania o možných dôsledkoch ich príliš rýchlej implemen-
tácie.
Kľúčové slová: preventívna medicína, genetické testy,
predpovedateľnosť, klinická validita, klinická užitočnosť,
etika  
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Article 9 – Consent
1 A genetic test may only be carried out after the per-
son concerned has given free and informed consent to it.
Consent to tests referred to in Article 8, paragraph 2,
shall be documented.
2 The person concerned may freely withdraw consent
at any time.
Article 10 – Protection of persons not able to consent
Subject to Article 13 of this Protocol, a genetic test on a
person who does not have the capacity to consent may
only be carried out for his or her direct benefit.
Where, according to law, a minor does not have the
capacity to consent, a genetic test on this person shall be
deferred until attainment of such capacity unless that
delay would be detrimental to his or her health or well-
being.
Article 11 – Information prior to authorisation, 
genetic counselling and support
1 When a genetic test is envisaged in respect of a per-
son not able to consent, the person, authority or body
whose authorisation is required shall be provided with
prior appropriate information in particular with regard
to the purpose and the nature of the test, as well as the
implications of its results.
Appropriate prior information shall also be provided to
the person not able to consent in respect of whom the
test is envisaged, to the extent of his or her capacity to
understand.
A qualified person shall be available to answer possible
questions by the person, authority or body whose autho-
risation is required, and, if appropriate, the person in res-
pect of whom the test is envisaged.
2 The provisions of Article 8, paragraph 2, shall apply in
the case of persons not able to consent to the extent of
their capacity to understand.
Where relevant, appropriate support shall be available
for the person whose authorisation is required.
Article 15 – Tests on deceased persons
A genetic test for the benefit of other family members
may be carried out on biological samples: removed from
the body of a deceased person, or removed, when he or she
was alive, from a person now deceased, only if the con-
sent or authorisation required by law has been obtained.
Additional Protocol to the Convention on Human Rights and Biomedi-
cine, concerning Genetic Testing for Health Purposes (2008)
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GENETIC TESTING FOR HEALTH PURPOSES
Regulatory Developments 
on the EU Level
Miroslav Mikolášik
European Parliament, Brussels (Belgium) – Strasbourg
(France) 
Ladies and gentlemen, dear guests,
It is my pleasure and honour to be here today. I would li-
ke to thank the organizers for invitation – especially Mrs.
Lawrence Lwoff from the Council of Europe, for the good
inter-institutional cooperation with European Parliament. 
In my presentation, I would like to focus on the revised
EU regulation in the field of genetic testing, which is co-
vered by in vitro diagnostics, highlighting several aspects.
The current EU regulatory framework for in vitro diag-
nostic medical devices ('IVDs') consists of Directive 98/
79/EC of the European Parliament and of the Council
('the IVD Directive'). IVDs cover a wide range of pro-
ducts that can be used for population screening and disea-
se prevention, diagnosis, monitoring of prescribed treat-
ments and assessment of medical interventions. Like
Council Directive 90/385/EEC on active implantable me-
dical devices (AIMDD) and Council Directive 93/42/EEC
on medical devices (MDD), the IVD Directive is based on
the 'New Approach' and aims to ensure the smooth func-
tioning of the internal market and a high level of protec-
tion of human health and safety. 
IVDs are not subject to any pre-market authorisation by a
regulatory authority but to a conformity assessment
which, for the majority of devices, is carried out under
the sole responsibility of the manufacturer. For the high-
risk devices and devices for self-testing, the conformity
assessment involves an independent third party, known
as 'notified body'. Notified bodies are designated and
monitored by the Member States and act under the cont-
rol of the national authorities. Once certified, devices
bear the CE marking which allows them to circulate
freely in the EU/EFTA countries and Turkey. 
The existing regulatory framework for in vitro diagnostic
medical devices has demonstrated its merits but has also
come under criticism in recent years. In an internal mar-
ket with 32 participating countries and subject to cons-
tant scientific and technological progress, substantial
divergences in the interpretation and application of the
rules have emerged, thus undermining the main objec-
tives of the Directive, i.e. the safety and performance of IVDs
and their free movement. This revision aims to overcome
these flaws and divergences and to further strengthen
patient safety. A robust, transparent and sustainable regu-
latory framework for in vitro diagnostic medical devices
that is 'fit for purpose' should be put in place. This frame-
work should be supportive of innovation and the com-
petitiveness of the in vitro diagnostic medical device
industry and should allow rapid and cost-efficient market
access for innovative IVDs to the benefit of patients and
healthcare professionals. 
This proposal is adopted alongside a proposal for a Re-
gulation on medical devices that are currently covered by
the AIMDD and the MDD. While the specific features of
IVDs and of the IVD sector require the adoption of a spe-
cific legislation distinct from the legislation on other me-
dical devices, the horizontal aspects common to both sec-
tors have been aligned.
Genetic Testing falls wihin the scope of the IVD directive
revision. Many people consider the IVD medical devices
regulation as the "small sister" of the Medical Devices Re-
gulation. In the Hearing we held last year in the Euro-
pean Parliament one of the experts said that the IVD me-
dical devices are not the "small sister" but the "parents" of
the Medical Devices and maybe the parents of all thera-
pies, including pharmaceutical products and surgery. 
Without a proper diagnostic there is no proper treatment
or prevention of diseases. Unfortunately the current di-
rective does not assure that low quality IVD medical devi-
ces are not placed on the market. In the past there have been
cases where a low quality HIV test was placed on the Eu-
ropean market with a CE-label. A scientific institute de-
termined already before the notified bodies approved the
CE-label that these tests announced much more false nega-
tive results than other HIV tests available which means
that the tests said there is no virus but in fact there is. How-
ever, this product was available for years for patients in
the EU. If a blood transfusion is performed on the basis
of a false negative result on HIV, this is a life-threatening
risk for the recipient of the blood transfusion. Another
example shows it has been reported that an expert for
DNA-Tests has sent the same sample to four different labo-
ratories and received four different results.
IVD medical devices are products that can circulate free
in the common market. There are no national borders for
these products in the European market. That is why it is
an obligation for the European Union to ensure the highest
possible safety. The proposal is based on article 114 and
168 of the Treaty. Article 114 asks for high protection of hu-
man health. Article 168, paragraph 4c gives even a specific
additional legal base.
The Commission includes major improvements to ad-
dress the current shortcomings of the system for IVD Me-
dical Devices similar to those for other medical devices.
The notified bodies will be substantially improved and
the supervision of the member states to the notified bo-
dies will be strengthened. Very important is that the sys-
tem of market surveillance and vigilance will be strengthe-
ned. Unannounced inspections of the companies will be
mandatory. Moreover, the Commission proposes to intro-
duce a network of European reference laboratories which
have an important role in the control of high-risk medi-
cal devices. 
Notified bodies system
However, some further strengthening of the proposed sys-
tem will enhance public safety, supervision and control
over the entire certification system. Tightened provisions
for the entire system concern closer supervision of the ex-
pertise that notified bodies should have inhouse as well
as the subsidiaries and external experts that they use in
the course of the conformity assessments they perform.
A newly introduced element to the COM proposal, nego-
tiated for both the medical devices and in vitro medical
device regulations, is the introduction of an enhanced
system for the highest risk classes devices, such as class D
in invitro diagnostic proposal. Only special notified bo-
dies with the requisite expertise to evaluate class D devi-
ces will be designated by the EMA to perform conformity
assessment for that highest risk class of devices.
In the European Parliament, three main improvements of
the commission's proposal were introduced:
1. The clinical performance study should be positively 
assessed by an independent ethics committee before 
it starts.
2. The protection of minors and other persons not able 
to give informed consent should be specified in the 
same way as in the directive of clinical trials in 2001.
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3. The timelines should be moderately extended to give 
the ethic committee and the authorities the necessary 
time to assess the proposal.
The acceptability for SMEs
In the area of in vitro diagnostic medical devices many com-
panies offering these devices are SMEs. That is why the
regulation needs to take into account the capacity of SMEs
to cover the burden. Of course this should not compro-
mise health and safety. For example it should be possible
to provide some requested information electronically
and it needs to be specified; that the information accom-
panied the product shall be provided in an official union
language and not in any other language. Both changes
reduce the potential burden for SMEs. Translation of dec-
larations of conformity into all official Union languages
where the device is made available is a disproportionate
administrative and thus cost-intensive effort, which is
not justified. Like at present, availability in one Union lan-
guage should be sufficient.
Classification
A completely new classification system (A-D) is proposed
(A=low risk device - D=high risk device). Most stakeholders
think it is appropriate and it is based on international
consensus.
In-house testing
In the current directive all in-house testing, which means
tests performed in a single health care institution, for
example in a hospital, is exempted from the requirements.
The commission proposed to keep this in principle for
the risk classes A, B, C but to include them fully when
tests are in class D. This needs to be slightly adapted with
respect to the needs of doctors and patients in a single
health care institution without dramatically changing the
concept of the European commission.
Companion diagnostics
Companion Diagnostics are DNA tests that give informa-
tion if a specific therapy would most lightly work in a spe-
cific patient. The huge opportunity of personalized and
stratified medicine needs to be addressed properly by
the regulation. The commission proposal is a good base
but needs to be further clarified. 
Self testing and near patient testing
Tests that are not performed by medical professionals
but by patients need to be regulated even more carefully
because medical professionals may include other ele-
ments of their diagnosis while laypersons may depend
their decision only on the test. It is subject to criticism
that the commission regulates self testing and near pa-
tient testing by medical professionals in the same way. 
Informed consent
The Commission proposal focuses very much on the qua-
lity of the product. Experts and many international orga-
nisations, like the Council of Europe, OECD and the Euro-
pean Society for Human Genetics have again and again
articulated their position that in many case even more
important than the quality of the product is the framework
in which the product is applied. Especially in DNA testing
it is very important to respect the principle of informed
consent. This has also been asked for by the European
Parliament several times. A legal opinion concludes that
it is possible and appropriate to introduce respective wor-
ding in the proposal. Therefore the rapporteur Mr. Peter
Liese MEP  proposed amendments on this issue. There is
consensus that it should not be the intention of the Eu-
ropean Union to limit the access of patients to DNA tests
but appropriate genetic counselling should be offered in
any case to inform about the consequences before a test
is performed. To respect the principle of subsidiarity it
should be left to the Members States to regulate the de-
tails and member states should have the option to go fur-
ther than the regulation requires. One can even argue
that it is mandatory to include informed consent in the
proposal because it is a crucial element of the Charta of
Fundamental Rights (Article 3) and the Charta of Funda-
mental Rights is legally binding for the European Union
in those areas where it acts.
Ladies and Gentlemen,
I believe revision of IVD directive as adopted in the Euro-
pean Parliament will find support in the Council so that
new legislation could be in force as soon as possible for
the benefit of patients and all citizens of the EU.
Thank you for your attention.
Correspondence to: Mr. Miroslav Mikolášik MD, MEP, European
Parliament, 60, Rue Wiertz, Altiero Spinelli 06F167, B-1047
Brussels, Belgium, e-mail: miroslav@mikolasik.sk
Article 12 – Authorisation
1 Where, according to law, a minor does not have the ca-
pacity to consent to a genetic test, that test may only be
carried out with the authorisation of his or her repre-
sentative or an authority or a person or body provided for
by law.
The opinion of the minor shall be taken into considera-
tion as an increasingly determining factor in proportion
to his or her age and degree of maturity.
1 Where, according to law, an adult does not have the
capacity to consent to a genetic test because of a mental
disability, a disease or for similar reasons, that test may
only be carried out with the authorisation of his or her
representative or an authority or a person or body provi-
ded for by law.
Wishes relating to a genetic test expressed previously by
an adult at a time where he or she had capacity to con-
sent shall be taken into account.
The individual concerned shall, to the extent of his or her
capacity to understand, take part in the authorisation
procedure.
Article 16 – Respect for private life and right to infor-
mation
1 Everyone has the right to respect for his or her priva-
te life, in particular to protection of his or her personal da-
ta derived from a genetic test.
2 Everyone undergoing a genetic test is entitled to know
any information collected about his or her health deri-
ved from this test.
The conclusions drawn from the test shall be accessible
to the person concerned in a comprehensible form.
3 The wish of a person not to be informed shall be res-
pected.
4 In exceptional cases, restrictions may be placed by law
on the exercise of the rights contained in paragraphs 2
and 3 above in the interests of the person concerned.
Additional Protocol to the Convention on Human Rights and Biomedi-
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THE OVIEDO CONVENTION AND ITS 
ADDITIONAL PROTOCOL CONCERNING
GENETIC TESTING FOR HEALTH PURPOSES
Laurence LWOFF
Bioethics Unit, Council of Europe, Strasbourg, France
The sequencing of the human genome and the develop-
ment of new technologies make human genetics a very
dynamic sector.  Knowledge on the human genome has
been a source of considerable advances, in particular the
development of genetic tests enabling the identification
of genetics characteristics responsible for a disease or, mo-
re frequently, involved in its development. 
The results of genetic tests are sensitive personal data, which
are often predictive with regard to the future health of
the person concerned, and are also shared with other
members of his or her biological family. These characte-
ristics raised a certain number of concerns in particular
with regard to the protection of privacy and the risk of
discrimination on the basis of genetic characteristics. 
These concerns have prompted the Council of Europe to
focus on the ethical and legal issues raised by applica-
tions of genetics, in particular genetic testing, and to draw
up legal standards to protect fundamental human rights
with regard to these applications.
Protection and guarantees in the fields of biology and me-
dicine, including human genetics, are provided by the Coun-
cil of Europe Convention for the Protection of Human
Rights and Dignity of the Human Being with regard to
the Applications of Biology and Medicine (Convention on
Human Rights and Biomedicine) (1). The Convention sets
out a number of principles concerning genetics (Articles
11 to 14), particularly genetic testing and interventions
on the human genome.
In order to develop and supplement the principles set
forth in the Convention, a new Additional Protocol to the
Convention on Human Rights and Biomedicine was elabo-
rated, concerning Genetic Testing for Health Purposes.
(2) This Protocol was adopted by the Committee of Mi-
nisters of the 47 Member States of the Council of Europe
on 7 May 2008 and opened for signature on 28 Novem-
ber 2008. (3) 
As underlined in the preamble of the Protocol, genetics
is contributing to the progress in biomedical sciences in
reducing morbidity and mortality and in improving the
quality of life.  Its objective is to protect against improper
use of genetic testing, by providing a framework for the
protection of fundamental rights and freedoms with re-
gard to such test.
The Protocol covers all genetic testing carried out for
health purposes, except those concerning the human emb-
ryo and foetus and that carried out for research purposes,
which are covered by another Additional Protocol to the
Convention on Human Rights and Biomedicine, concer-
ning Biomedical Research. 
In the drafting of the Protocol, a certain number of issues
were raised and examined, in particular: the quality of
genetic testing; the capacity of analysis which keeps on
increasing but is not necessarily followed by a similar
capacity to act either to prevent the development of the
disease concerned or to treat it; the complexity of the
interpretation of the test results as well as the difficulty
for the person concerned to understand all its implica-
tions; the protection of the person not able to consent;
the confidentiality and security of data and samples.  
The field of genetics is technically complex and constant-
ly evolving. Different experts in genetics were consulted
and the recommendations of the European Society of Hu-
man Genetics as well as the OECD guidelines on quality
assurance in molecular genetic testing were taken into
account.
This was particularly important for the elaboration of the
provisions concerning genetic services. Article 5 on quali-
ty of genetic services, requires that genetic tests meet
generally accepted criteria of scientific validity and clini-
cal validity.  
Particular emphasis is also placed on the importance of
taking into account the clinical utility of genetic test as
an essential criterion for deciding to offer this test to a
person or a group of persons. It has to be an integral part
of a good medical practice with regard to any decision to
carry out a test. This was considered of particular impor-
tance for tests proposed outside any individualized medi-
cal supervision. 
Information and genetic counseling as well as tests di-
rectly accessible were two issues which were particularly
discussed during the preparation of the Protocol. 
The Convention on Human Rights and Biomedicine requi-
res in its Article 12 that “tests which are predictive of ge-
netic diseases or which serve either to identify the subject
as a carrier of a gene responsible for a disease or to de-
tect a genetic predisposition or susceptibility to a disease
may be performed only for health purposes or for scien-
tific research linked to health purposes, and subject to
appropriate genetic counseling.” These requirements are
reiterated in Article 8 of the Additional Protocol. The ex-
pression “appropriate genetic counseling” has been fur-
ther discussed in the framework of the elaboration of the
Additional Protocol. The Explanatory Report to Article 8
of the Additional Protocol specifies that genetic counse-
ling is an individualized process taking into account, in
particular, the psychological and family context of the
person concerned and involving an exchange between
him or her and the person providing the counseling. Ge-
netic counseling could vary in form and extent in accor-
dance in particular with the implications of the test and
their significance for the person concerned or the mem-
bers of his or her family, including possible implications
for procreation choices. Genetic counseling could thus
go from a “very heavy and long” procedure to a “lighter”
one which may be limited to a pre-test counseling, hence
the adjective “appropriate”.
The quality of the prior information given to persons en-
visaging genetic testing, designed to enable them to take
an informed decision, as well as the support provided to
persons taking such decisions and dealing with the impli-
cations of a test and its results, were underlined. The Pro-
tocol thus lays down (Article 7.1) the general rule that
genetic testing for health purposes may be carried out
only under individualised medical supervision. According-
ly, such testing should be carried out only in response to a
specific indication made on the basis of a precise evaluation,
by a doctor, of the situation of the person concerned.  
In this context, the issue of tests that are directly availab-
le to the individuals i.e. outside any conventional medical
system, was specifically considered.
The Protocol prohibits exceptions to the general rule de-
fined in Article 7.1 in the case of genetic testing with im-
portant implications for the health of the person concer-
ned or his or her family members or for procreation
choices. 
The key concerns here are the proper interpretation of
predictive tests results and the guarantee of an appropria-
te genetic counselling to understand its implications.
The results of such genetic tests may be particularly comp-
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lex to interpret and may, for instance, require that addi-
tional medical information or information about the fami-
ly history be taken into account. In the case of many pre-
dictive tests, even though the test may reveal a high proba-
bility of developing a particularly serious disease, the
time of onset of the disease and the severity of the symp-
toms are often uncertain. Lastly, the problem of under-
standing the nature of the test and the implications, in-
cluding the implications for family members, the poten-
tial psychological impact of the results on the person
concerned and the often important decisions facing that
person require that such tests be carried out under indi-
vidualised medical supervision. 
The Protocol does, however, provide that states under cer-
tain conditions may make exceptions to the general rule
in the case of tests that would not have serious implica-
tions, the principal aim being to ensure compliance with
the provisions of the Protocol concerning the nature and
quality of the prior information, free and informed con-
sent and genetic counselling (Article 7.2). 
Each state therefore has a degree of discretion, in the
decision to allow a test to be carried out without individua-
lised medical supervision, and when it comes to the pro-
cedures to be followed and the bodies involved in this
process.
However, as the objective is to protect the person concer-
ned, particular account must be taken of the importance
of the potential implications of the test in question for
the person on whom it is to be carried out or his or her
family members, the ease of interpretation of the results
and, where appropriate, the treatment possibilities for
the disease or disorder concerned. 
On that basis, the Council of Europe will continue to follow
the evolution of the offer of directly accessible tests with
a view to facilitating the implementation of the princip-
les laid down in the Protocol.  
With the assistance of the European Society of Human Ge-
netics and EuroGentest, the Council of Europe has alrea-
dy published leaflet, which provides general objective
information on genetic testing, including on their nature
and the potential implications of their results. It presents
the different type of tests available, their application in
the medical field and the extent and limit of the signifi-
cance of the information resulting from these tests. It con-
tains a specific section on direct to consumer genetic tes-
ting. It is currently available in 29 European languages at
www.coe.int/bioethics
Current activities relevant to genetics
After genetic testing for health purposes, the intergovern-
mental Committee on Bioethics (DH-BIO) is now wor-
king on the processing for insurance purposes of health-re-
lated data, in particular data resulting from genetic tests
with a view to the elaboration of a new recommendation. 
Furthermore, the DH-BIO is re-examining Recommenda-
tion (2006)4 on research on biological materials of hu-
man origin, in the light of experience acquired and de-
velopments in the field concerned since the adoption of
that legal instrument. 
A public consultation on a working document took place
on March-August 2014. The comments received will now
be analysed with a view to prepare the final version of
the revised recommendation to be presented to the Com-
mittee of Ministers for adoption. 
Further information on the work of the Council of Eu-
rope as well as adopted legal instruments in the field of
bioethics can be found at http://www.coe.int/bioethics.
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Article 17 – Biological samples
Biological samples referred to in Article 2 shall only be used
and stored in such conditions as to ensure their security
and the confidentiality of the information which can be ob-
tained therefrom.
Article 18 – Information relevant to family members
Where the results of a genetic test undertaken on a person
can be relevant to the health of other family members, the
person tested shall be informed.
Additional Protocol to the Convention on Human Rights and Biomedi-
cine, concerning Genetic Testing for Health Purposes (2008)
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Legal Situation and Perspectives 
for Ratification of the Additional Protocol
on Genetic Testing For Health Purposes
COUNTRIES INFORMATION1
ARMENIA
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): not ratified.
2. Does your country have any legislation or regulations 
covering genetic testing for health purposes? Please 
specify.
National legislations covering genetic testing for health
purposes are regulated by the official Act and license of
the Ministry of Health (Act No. 153: 1998; license No K-
BO-66167). This Act sets out the provision on the use of
genetic testing developed for medical purposes and of
certain legal regulations. Regarding reasonably not large
population of Armenia (approximately 3 million), the Cen-
ter of Medical Genetics and Primary Health Care (CMG)
is provided as a unique medical genetics service. The man-
date of CMG is to support investigations on the human
genome and on all aspects of human genetics related to
health and diseases, including the translation of know-
ledge into health policy and practice, and the societal imp-
lications of genetic discoveries. The specialists of CMG per-
form genetic testing for molecular diagnostics of large
spectrum of hereditary disorders and birth defects, male
and female infertility, recurrent pregnancy loss, cancer,
haematological, neurological, neuro-muscular, autoin-
flammatory, cardiologic diseases, including genetic coun-
selling of patients and families and prenatal diagnostics
of pregnant women. CMG carriers out the collection and
storage of DNA of genetic disorders according to the bio-
ethical laws: consent form, record the personal and medi-
cal information, and collect the blood/DNA samples with
the personal barcode. Personal confidential information
of thousands of persons with different genetic disorders
is stored in the existing CMG Genetic Database for more
accurate patient diagnosis and the associated impact on
better treatment. The requirements for the development
of genetic investigations, including genetic services for
health care system, genetic data protection, and ethical
aspects of genetic testing are regulated by the Armenian
society of human genetics. 
Sex selection is a huge problem in some countries, whe-
re the selective abortion has been practiced. Council of
Europe could provide assistance for an exchange of views
on situation in member states to facilitate the Protocol
concerning the tests for health purposes, including ge-
netic counselling, prenatal diagnostics. The assistance
should be focused on educational programs for health
professionals and targeted populations, considering a
legislation banning gender detection before the 22nd week
of pregnancy. Prenatal sex selection is indicated by a “ske-
wed sex ratio”, meaning a departure from the natural ave-
rage sex ratio at birth. Resolution of the Parliamentary
Assembly of the Council of Europe expressed concern over
the skewed sex ratios at birth has been observed in a num-
ber of Council of Europe member states, including Arme-
nia, where the sex ratio at birth is more prevalent for boys.
Statistic shows an unnatural prevalence of boys among
the children under 15 years old in some populations. Preg-
nant women should be offered general information about
prenatal diagnostics an interpretation about health of foetus.
In 2004-2006 European Health Committee (CDSP) of
Council of Europe developed the Recommendations on
impact of genetics on the organization of health care ser-
vices and training of health professionals (myself as the
expert). Recommendation CM/Rec(2010)11 of the Com-
mittee of Ministers to member states: CDSP identified
medical genetics as a medical specialty at the European
level, and provided recommendation on the impact of ge-
netics on the organization of health care services and trai-
ning of health professionals in the European community.
Ministry of Health of Armenia recognized Medical Gene-
tics as a medical specialty in 2010, and in 2011 depart-
ment of medical genetics was established at Yerevan sta-
te medical university; the educational program is guided
by these recommendations. 
3. What assistance could the Council of Europe provide 
to facilitate progress in your country towards the rati-
fication procedure?
The Convention on Human Rights and Biomedicine (Ovie-
do Convention) contains very important for Armenia pro-
visions relating to genetics, including predictive genetic
tests and interventions on the human genome. The ratifi-
cation of this protocol must be performed by the Parlia-
ment of Armenia. The Additional Protocol concerning Ge-
netic Testing for Health Purposes is also very important
for the development of genetic service in Armenia, be-
cause the CMG serves as the only genetic institution for
health purposes. As a central and beneficial deed in reali-
zation of the ratification procedure of the Oviedo con-
vention and its additional protocol our service in medical
genetics needs professional consultations and training,
including participation in DEBRA conferences. Informa-
tion of the additional protocol about genetic counselling
seems to be very important for family doctors and other
medical professionals, because it is unsufficient in the
field of bioethics, newborn screening, and genetic tes-
ting of multifactorial and rare diseases. In particular, the
document must be developed to cover general principles
related to the functioning of genetic service in the field
of reproduction to investigate the reasons of skewed sex
ratios at birth, organise and support public awareness-rai-
sing conferences on prenatal sex se-lection, sex-selective
abortions as common practice in some communities, par-
ticularly in case of the third or fourth child.
The Council of Europe could be very helpful in assisting
in explanation of the actuality of Oviedo Convention and
Additional Protocol to the Ministry of Health of Armenia
(I am the chief specialist-geneticist of the Ministry of Health)
and the Permanent Representative of Armenia to the Coun-
cil of Europe. 
Responses by: Sarkisian Tamara 
Institution: Center of Medical Genetics and Primary
Health Care
BOSNIA AND HERZEGOVINA
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): ratified.
2. Does your country have any legislation or regulations 
covering genetic testing for health purposes? Please 
specify.
No. Currently, the only legislature concerning the genetic
testing in Bosnia and Herzegovina is found as part of health
1Based on the material Replies by country. Questionnaire for the
participants at the International Bioethics Conference on Genetic
Testing for Health Purposes in Central and Eastern Europe, May 29-
30, 2014, Bratislava, Slovak Republic, compiled by the Secretariat of
the Committee on Bioethics (DH-BIO) of the Council of Europe. The
texts contained in the Proceedings edited by J. Glasa & H. Glasová.
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legislatures concerning other health issues that are in
some way involving genetic testing. Therefore, at pre-
sent, there is no legislature concerning only genetic tes-
ting in Bosnia and Herzegovina. 
3. If not, is it foreseen to introduce any legislation/regu-
lations? 
Once the legal pre-requirements for the Additional Pro-
tocol concerning Genetic Testing for Health Purposes have
been met, this protocol will be implemented as one form
of regulation of genetic testing for the health purposes.
4. If your country has ratified the Oviedo Convention, 
but not it’s Additional Protocol concerning Genetic 
Testing for Health Purposes, what are the current pos-
sible obstacles to this ratification?
Bosnia and Herzegovina signed (16.12.2005.) and rati-
fied (11.05.2007) the Council of Europe Convention on
the Protection of Human Rights and dignity of the hu-
man being with regard to the Application of Biology and
Medicine (Oviedo Convention) and the Additional Pro-
tocol on biomedical research. 
During the meeting of the Committee on Bioethics (DH -
BIO), the Council of Europe, held in Strasbourg on 19-22
June in 2012, Bosnia and Herzegovina was encouraged to
start the procedure for signing the additional protocols to
the Convention (Additional Protocol to the Convention
on Human Rights and Biomedicine concerning Transplan-
tation of Organs and Tissues of Human Origin; Additio-
nal Protocol to the Convention on Human Rights and Bio-
medicine, concerning Genetic Testing for Health Purpo-
ses; and Additional Protocol to the Convention for the Pro-
tection of Human Rights and Dignity of the Human Being
with regard to the Application of Biology and Medicine, on
the Prohibition of Cloning Human Beings).
Out of those three, only the last one (the Prohibition of
Cloning Human Beings) has received full support from
the competent health authorities in Bosnia and Herzego-
vina, while for the other two (concerning transplanta-
tion and genetic testing) legal pre-requirements have not
been met as yet.  
The Council of Ministers of B&H on its 72nd Session held
on 28 November 2013, adopted and the Presidency of B&H
on its 45th Session held on 26 March 2014, endorsed the
Decision on acceptance of the Additional Protocol to the
Council of Europe Convention on the Prohibition of Clo-
ning of Human Beings. The Protocol will be signed soon
by the empowered Ambassador of Bosnia and Herzegovi-
na to the Council of Europe. 
Hence, the Additional Protocol to the Convention on Hu-
man Rights and Biomedicine, concerning Genetic Tes-
ting for Health Purposes still remains unsigned.
5. What assistance could the Council of Europe provide 
to facilitate progress in your country towards the rati-
fication procedure?
Consultations, trainings and workshops on ratification
and implementation of the Protocol concerning Genetic
Testing for Health Purposes for the competent authori-
ties in B&H.
Responses by: Nina Maric (1), Aida Saracevic (2)
Institutions: (1) Clinical Center Banja Luka, (2) Centre
for Genetics, Medical Faculty, University of Sarajevo
ESTONIA
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): ratified.
2. Does your country have any legislation or regulations 
covering genetic testing for health purposes? No.
3. If not, is it foreseen to introduce any legislation/regu-
lations? Data not available.
4. If your country has ratified the Oviedo Convention, 
but not it’s Additional Protocol concerning Genetic 
Testing for Health Purposes, what are the current 
possible obstacles to this ratification? Taken into the 
agenda.
5. What assistance could the Council of Europe provide 
to facilitate progress in your country towards the rati-
fication procedure? None.
Responses by: Vaike Leola
Institution: Estonian National Bioethics Committee
LATVIA
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): ratified.
2. Does your country have any legislation or regulations 
covering genetic testing for health purposes? Please 
specify.
The Human Genome Research Law ((hereinafter – the Law),
from 13th of June 2002, valid from the 1st of January 2004)
and the Regulation of the Cabinet of Ministers of the
Republic of Latvia No.692 “Procedures for Genetic Re-
search” (adopted on 10 August, 2004) are the main regu-
lations in Latvia covering genetic testing. In addition to
these regulations we have another regulation on genetic
scope. 
● The Law defines the general principles of human ge-
nome research, emphasizing that in genetic research 
the interests, rights and protection of a gene donor 
shall be set higher than the interests of society and 
science.
● The purpose of the Law is to regulate the establish-
ment and operation of the single genome database of 
the State population (hereinafter – genome database) 
and genetic research, to ensure the voluntary nature 
and confidentiality of the gene donation in respect of 
the identity of gene donors, as well as to protect per-
sons from the misuse of genetic data and the discrimi-
nation related to the genetic data.
The Law regulates:
– the provisions for the tissue sample processing, 
preparation of the description of the DNA, descrip-
tion of the state of health and genealogy in relation 
to the genome database;
– the genetic research regulations in relation to the 
genome database and organization of the supervi-
sion of such research;
– the rights and obligations of gene donors, activity of 
the chief processor, authorized processor of the 
genome database and gene researchers;
– the restrictions in relation to the use of tissue samp-
les, the use of descriptions of the DNA compiled in 
the genome database, descriptions of the state of 
health and genealogy; 
– coding and decoding provisions.
● The Law prescribes that the gene donor participates 
voluntarily in the genetic research. It is prohibited to 
discriminate against a person in relation to his or her 
genetic origin and any other data acquired as the re-
sult of the genetic research, as well as on the basis of 
the fact that the person is or is not a gene donor.
● The Law prescribes that genetic research is permitted 
for the purpose of studying and describing the mutual 
connection between genes, the human state of health, 
lifestyle and physical and social environment, in or-
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der to discover, on the basis of such research, disease 
diagnostic and treatment methods that will help to 
assess the health risks of the individuals and to pre-
vent the causes of diseases.
● Genome research of a deceased person may not be per-
formed if this is against his or her expressed will whi-
le alive. If such a will was not expressed, it is prohibi-
ted to perform the genome research of the deceased 
person.
● The Law defines the Consent to Become a Gene Do-
nor and Rights of Gene Donors, for example, before a 
person participates in the genetic research, a doctor 
shall issue to the person written information regarding:
– the purpose, content and duration of the genome re-
search project;
– potential risks; 
– the right to freely express his or her consent and to 
revoke it at any time; 
– a possibility to perform genetic research outside of 
Latvia;
The consent of a person to take tissue samples from him
or her, to prepare and supplement the description of the
state of health or the genealogy, to include such descrip-
tion in the genome database and use it in the genetic re-
search and for the purpose of statistics, to bring it out of
Latvia, as well as to use the genetic data shall be provided
in writing. The consent document of a gene donor shall
be prepared in two copies; the document shall be signed
and dated by the gene donor or his or her guardian or
trustee and the chief processor or the authorized proces-
sor. One copy of the consent document shall be kept in
the State Population Genome Register; the other copy shall
be issued to the gene donor or his or her guardian or
trustee.
● The State Population Genome Register shall keep the 
consent document of a gene donor for 75 years after 
the last entry characterizing the tissue samples, the des-
cription of the state of health and the description of 
the DNA.
● The Law also describes the Operations with Tissue 
Samples, Descriptions of the State of Health, Genealo-
gies, DNA Descriptions and Personal Data of the Gene 
Donor as well as Requirements for Coding and Reco-
ding and Supervision and Procedures for Examination 
of Complaints.
We have established the Single Genome Database in 2006.
The chief processor of the genome database is Latvian
Biomedicine Research Institute. The tasks of the chief
processor are following:
– to organize the taking and storage of tissue samples, 
the preparation, storage and destruction of descrip-
tions of the state of health and genealogies;
– to perform the coding;
– to perform the genetic research and to collect, sto-
re, destroy or issue the genetic data;
– to provide the State Population Genome Register 
with the genetic data acquired as the result of the 
genetic research related to a particular gene donor;
– to promote the development of genetic research in 
Latvia; and
– to promote the utilization of the results of the ge-
netic research for the improvement of health of the 
person and the whole of society.
● If the genetic research is performed irrespective of the 
genome database, the information regarding the state 
of health of the person, tissue samples and descrip-
tions of the DNA shall be included in the genome da-
tabase only upon a written consent of the gene donor. 
In such case, a gene researcher has the right to work 
with the tissue samples, which he or she has collected 
and stored in a ge-nome database, within the scope of 
their powers as prescribed by the Law.
● The full text of the Law in English is available at: http: 
//www.vvc.gov.lv/export/sites/default/docs/LRTA/ 
Likumi/Human_Genome_Research_Law.doc
● The Regulation of the Cabinet of Ministers of the Re-
public of Latvia No.692 “Procedures for Genetic Re-
search” (adopted on 10 August, 2004)
● The Regulations determines the procedures for gene-
tic research and the documents that must be provided 
to allow the launch of genetic research (the positive 
opinion of the Genome Research Council and the po-
sitive opinion of the Central Medical Ethics Commit-
tee). The Regulations prescribes that in the genetic re-
search only coded tissue samples, coded descriptions 
of DNA, coded state of health may be used. 
3. If your country has ratified the Oviedo Convention, but 
not its Additional Protocol concerning Genetic Tes-
ting for Health Purposes, what are the current possib-
le obstacles to this ratification? 
Latvia has ratified the Oviedo Convention. Currently Latvia
has started work on the ratification of the Additional Pro-
tocol concerning Genetic Testing for Health Purposes. We
have evaluated the national legislation on genetic testing.
It is planned to ratify the Additional Protocol in the near
future.
Responses by: Ēriks Miītis
Institution: Ministry of Health of the Republic of Latvia
LITHUANIA
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): ratified.
2. Does your country have any legislation or regulations 
covering genetic testing for health purposes? Please 
specify. 
● National standards for genetic counselling and pro
fessional responsibilities of clinical geneticists are re-
gulated by the Act No. V-220/2003 of the Ministry of 
Health.
● Specific requirements for the provision of genetic ser-
vices (i.e. the requirements for the specialists provi-
ding genetic services, premises, medical devices and 
other medical equipment, organization of provision 
of this services) are established in 2012 (Act. No. V-745/ 
2012 of the Ministry of Health).
● Genetic services are a part of the Lithuanian health care 
system. They are paid by the National health insu-
rance fund under certain medical indications, listed 
in 2005 (Act. No. V-522/2005 of the Ministry of Health).
● Universal newborn screening for inherited metabolic 
diseases is performed following the procedure estab-
lished in 2004 (Act No. V-865/2004 of the Ministry of 
Health).
3. If your country has ratified the Oviedo Convention, 
but not its Additional Protocol concerning Genetic Tes-
ting for Health Purposes, what are the current possib-
le obstacles to this ratification?
● There might be an uncertainty with regard to imple-
mentation of some provisions of the Protocol, parti-
cularly with regard to the provisions of the Article 5, 
Article 8, since according to Kucinskas et al, there is a 
relatively low number of specialists providing gene-
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tic services for the population of Lithuania in compari-
son to the leading West European countries. Also the-
re is an absence of standards and appropriate training 
for the specialty “medical geneticist”; graduate non-
MD medical geneticists must be further trained at their 
working place, but there are no system and budget 
for such training.
4. What assistance could the Council of Europe provide to 
facilitate progress in your country towards the ratifi-
cation procedure?
Similar conferences as the one being organized now would
help to increase the awareness of the Protocol as well as
to facilitate progress towards the ratification procedure.
Responses by: Jurate Lekstutiene
Institution:  Lithuanian Bioethics Committee
MOLDOVA
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): ratified.
2. Does your country have any legislation or regulations 
covering genetic testing for health purposes? Please spe-
cify.
Law Nr. 1256  from  19.07.2002
http://lex.justice.md/index.php?action=view&view=doc
&lang=1&id=352146
3. If your country has ratified the Oviedo Convention, but 
not it’s Additional Protocol concerning Genetic Testing 
for Health Purposes, what are the current possible obs-
tacles to this ratification?
Partly, containing of Additional Protocol, referring to re-
search on embryos and cloning of human is reflected in
the Law Nr. 138 from 15.06.2012,
http://lex.justice.md/index.php?action=view&view=doc
&lang=1&id=344838
4. What assistance could the Council of Europe provide 
to facilitate progress in your country towards the rati-
fication procedure?
The representatives of CoE to come and work in a team
with representatives of the Ministry of Health of Moldova,
local legal authorities and genetic researchers.
Responses by: Natalia Usurelu
Institution:  Institute of Mother and Child, Centre of Rep-
roductive Health and Medical Genetics
MONTENEGRO
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): ratified on March 19, 2010.
2. Does your country have any legislation or regulations 
covering genetic testing for health purposes?
There are several laws in Montenegro, which cover diffe-
rent aspects of genetic testing for health purposes:
● The Law on genetic data protection (Published in 
“Official Gazette of Montenegro“, no. 25/2010, www. 
mzdravlja.gov.me).
● The Law on collection and utilization of biological 
samples (published in the “Official gazette of Monte-
negro, no. 14/2010, www.mzdravlja.gov.me) 
● The Law on Infertility Treatment with Assisted Repro-
ductive Technologies (published in the “Official ga-
zette of Montenegro”, no. 74/2009, www.mzdravlja. gov. 
me)
● The Law on the conditions and procedures for artifi-
cial termination of pregnancy, 27 July 2009.
● The Law on removal and transplantation of human bo-
dy parts for the purposes of medical treatment (pub-
lished in the “Official gazette of Montenegro”, no. 
76/2009, www.mzdravlja.gov.me)
The Law on genetic data protection 
The Law on genetic data protection plays the central role
regarding the most important medical and ethical aspects
of genetic testing use, with respect to protection of the
most important human rights regarding genetic testing. 
The crucial reasons for passing the Law on genetic data
protection were: demand of regulating the collection, use,
processing and storage of human genetic data and sam-
ples, with special focus on protection of privacy, dignity,
integrity, identity and other personal rights and freedoms;
necessity to regulate conditions for the genetic testing pro-
cedures - performed only for diagnostic, predictive, pre-
ventive and therapeutic purposes; need to prevent discrimi-
nation and stigmatization against an individual, family, or
community groups, due to their genetic traits known by
genetic testing. 
The Law on the protection of genetic data is consistent with
the International/European legislation: 
– Convention on Human Rights and Biomedicine, 
– Additional Protocol to The Convention on Human Rights 
and Biomedicine, concerning Genetic Testing for Health 
Purposes - adopted by the Council of Europe and
– International Declaration on Human Genetic Data,
– Universal Declaration on Human Genome and Hu-
man Rights,
– Universal Declaration on Bioethics and Human Rights - 
adopted by UNESCO.
General provisions and aims of this Law refer to:
– collecting, using, processing and storage of human ge-
netic data and samples, obtained by genetic testing and 
analysis performed for health purposes,  
– genetic testing and genetic analyses conducted within 
genetic investigations in people, including prenatal ge-
netic investigations of embryo and foetus during ferti-
lization and pregnancy;
– protection of identity, privacy, respect for human dig-
nity personal integrity, equality, free decision and self-
determination, including the right to genetic informing 
and counselling prior to, and after the conducted testing;
– determination of the terms of references for medical 
institutions and medical professionals, ensuring appro-
priate quality of genetic services (genetic testing and ge-
netic informing and counselling), consistent with bio-
ethical recommendations and directives.
Provisions of this Law do not refer to determining pater-
nity or maternity, as well as to the scientific research work.
Genetic pretesting information, written consent and ge-
netic counselling and reporting the results after perfor-
ming genetic testing are mandatory actions and have to
be conducted by responsible doctor in written form.
Law on genetic data protection demands compulsory evi-
dence and registries of medical institutions, that perform
genetic testing and collecting of genetic data and samp-
les, and also demands regulatory bodies monitoring and eva-
luation.  
The other, above mentioned Laws cover different aspects
of genetic testing, such as gender sensitive issues and clear-
ly prohibit genetic testing and consecutive prenatal sex se-
lection, except for health purposes: 
● “After prenatal genetic testing it is not allowed to inform 
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future parents about sex of embryo, before the comp-
letion of 12th week of pregnancy. Exception is for the 
prenatal genetic testing when sex determination for 
medical purposes is indicated by responsible medical 
doctor (clinical geneticist).” - Law on genetic data pro-
tection. 
● “It is not permitted to conduct prenatal genetic tes-
ting in early pregnancy (up to 10 weeks of gestation), 
to sex determination, except when there are sex rela-
ted risks for genetic disorder, indicated by clinical ge-
neticist.” - Law on the conditions and procedures for 
artificial termination of pregnancy. 
● Law on the treatment of infertility, with assisted repro-
ductive technologies, prescribes the obligation of me-
dical institutions that conduct assisted reproduction 
technologies to form the Medical Board, including me-
dical doctor certified in medical/clinical genetics, as a 
mandatory member.  
3. If your country has ratified the Oviedo Convention, 
but not it’s Additional Protocol concerning Genetic 
Testing for Health Purposes, what are the current pos-
sible obstacles to this ratification?
Montenegro has ratified Additional Protocol concerning
Genetic Testing for Health Purposes on 12 February 2013. 
4. If your country has already ratified the Additional Pro-
tocol, what assistance could the Council of Europe pro-
vide to facilitate its implementation?
The ratification of Convention on Human Rights and Bio-
medicine (Oviedo Convention) and its Additional Proto-
col concerning Genetic Testing for Health Purposes, and
also passing of several national laws and regulations, that
cover genetic testing for health purposes, present a good
framework for human rights protection in the field of bio-
medicine. 
Regarding Montenegro population characteristics (popu-
lation of approx. 670.000, multiethnic, life expectancy
73/76 years man/women respectively, live births approx.
8000/year, infant mortality rate < 6/1000), medical gene-
tics service in Montenegro is provided as a unique centra-
lized service at the tertiary health care level in the Clini-
cal Centre of Montenegro. Centre for medical genetic and
immunology at the Clinical Centre of Montenegro provi-
des genetic service including clinical genetics, register of
genetic diseases, prenatal and postnatal genetic testing for
most common genetic disorders, pre- and post-testing ge-
netic counselling. 
Principles of genetic testing, informing and counselling
are based on contemporary bioethical statements and
Convention on Human Rights and Biomedicine (Oviedo
Convention) and its Additional Protocol concerning Gene-
tic Testing for Health Purposes. Within medical genetics ser-
vice all patients in need of genetic testing are provided
with pretesting counselling and written information, writ-
ten consent, genetic testing results interpretation, post-tes-
ting genetic counselling and written genetic information,
comprehensible and non-directive counselling that are
provided ex-clusively by a medical doctor - clinical/medical
geneticist.
Several laws which have been passed a few years ago, and
experiences from the activities in the field of medical and
clinical genetics in Montenegro made an appropriate am-
bient for further goals in the field of bioethics, but some
pending issues still exist. Rapid “genetization” of medi-
cine requests our presence, alertness and quick response
in protecting against any misuse of genetics achieve-
ments and in defending human rights. Accumulated know-
ledge under lines the need to promote ethical aspects
connected with genetic testing and research, as well as
necessity for better education of medical professionals
and general population, preparing them for appropriate
social and legal response to the emerging ethical issues. 
Common knowledge about medical genetics and genetic
testing for health purposes within the general population
still seems to be insufficient in Montenegro. Also general
practitioners, family medicine doctors and other medical
professionals, who are not involved in medical genetic
services, need better education due to recent advances in
the field of medical genetics and genetic testing. Further-
more, spreading of private medical services, which are
not always integrated in the national health system, has
brought a different approach and genetic knowledge
implementation in the field of genetic testing for health
purposes, not always consistent with the national Law. 
Future actions should be undertaken to provide comp-
lete coverage of Law implementation, focusing on:
– promotion of genomic health and bioethics in the 
field of medical genetics;   
– investigation on general population and medical pro-
fessionals regarding the knowledge and attitudes to-
ward genetic testing and bioethical issues;
– developing the “behaviour change communication 
strategy” to prevent misuse of genetic testing and to avoid 
prenatal sex selection in private medical institutions, 
and in the neighbouring countries;
– developing educational programs and organizing edu-
cation in the field of bioethics focused on medical pro-
fessionals and general or targeted population;
– provision the quality of genetic services, pre- and post-
testing genetic counselling and prenatal diagnostics, 
and alignment the medical genetics and bioethics stan-
dards; 
– development of regulatory bodies activities toward 
continuous monitoring and evaluation of human rights 
protection in bioethics;
– spreading regional integration and cooperation.
Possible Council of Europe assistance could be focused
on the support of several activities/areas:
– expertise for promotion of ethical aspects of genetic tes-
ting and research, especially for prenatal and precon-
ception genetic testing, genetic counselling and of ge-
nomic health; 
– expertise for investigation on general population and 
medical professionals regarding knowledge and atti-
tudes toward genetic testing and bioethical issues;
– expertise for developing “behaviour change communi-
cation strategy”, regarding changing attitudes towards pre-
natal sex selection among general population, but also 
among medical professionals;
– organization of regional round tables and conferen-
ces with the purpose of exchanging experiences in the 
field of preparation and implementation of legislation 
regarding genetic testing for health purposes;
– support in the education and training of medical and 
other professionals in the field of bioethics.
Responses by:  Olivera Miljanovic
Institution: Centre for Medical Genetics and Immunology,
Clinical Centre of Montenegro, Medical Faculty, University
of Montenegro
SERBIA
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): ratified.
2. Does your country have any legislation or regulations co-
vering genetic testing for health purposes? Please specify. 
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The only legislation concerning genetic testing in Serbia
is found as a part of the health legislatures concerning
other health issues, as the Law on Health Care and the Law
on Infertility Treatment using procedures of medically
assisted fertilization. Serbia has detailed prescriptions on
professional education and training of medical profes-
sionals (medical doctors) in the discipline of medical
genetics. Serbia do not have clinical genetics specializa-
tion at the University of Belgrade, but introduced labora-
tory medicine, which lasts four years, and students will
learn clinical genetics. Laboratory professionals work in
eight public and in three private genetics laboratories.      
3. If your country has ratified the Oviedo Convention, 
but not it’s Additional Protocol concerning Genetic Tes-
ting for Health Purposes, what are the current possib-
le obstacles to this ratification? 
The ratification of Convention on Human Rights and Bio-
medicine (Oviedo Convention) cover some issues in ge-
netic testing but the Additional Protocol Concerning Ge-
netic Testing for Health Purpose has to be ratified in or-
der to have a good framework for the protection of hu-
man rights in the field of biomedicine. Common know-
ledge among medical doctors, other medical professionals
and general public in Serbia about medical genetics and
genetic testing needs better education due to the advan-
ces in the field of biomedicine. Serbia has to establish
national reference laboratory for all specific issues in ge-
netic testing with the well-educated staff, adequate space
and equipment.  
4. What assistance could the Council of Europe provide 
to facilitate progress in your country towards the rati-
fication procedure?
We need assistance, consultations/workshops for the me-
dical professionals and competent authorities. Organiza-
tion of regional round tables with a purpose of exchan-
ging experience in the field of bioethics.  
Responses by: Nada Vasiljevic
Institution: Direction of Biomedicine, Ministry of Health
of Serbia
SLOVAKIA
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): ratified.
2. Does your country have any legislation or regulations 
covering genetic testing for health purposes? Please 
specify.
Slovak Republic (Slovakia) does not have a specific legis-
lation on just genetics testing for health purposes as such,
but her extensive legislation framework of health, health
care, and health care system legislation (in particular the
Law No.576/2004 Coll. on health care, and Law. No.
578/2004 Coll. on health care providers, both as later amen-
ded); data protection legislation (Law. No. 122/2013 Coll.
on protection of personal data (superseding previous
law on the same subject)); human rights protection legis-
lation; family and citizens legislation are applicable as
appropriate also to the area of genetic testing for health
purposes, including for biomedical research and drug
clinical trials. More detailed analysis is beyond the scope
of this questionnaire.    
Slovakia posses also detailed legislation and related pres-
criptions on professional education and training of me-
dical professionals (medical doctors) in the discipline of
medical genetics, as well as outlining the necessary con-
ditions for practicing medical genetics within the Slova-
kia’s health care system. The same holds for the laborato-
ry professionals in genetics laboratories. 
Slovakia has a specific Law No. 417/2002 Coll. (as later
amended) on the use of DNA for the identification of
persons. 
Slovak Society of Medical Genetics (SSMG), branch of the
Slovak Medical Association, issues professional guide-
lines for her members and for the medical genetics cent-
res and laboratories in Slovakia. The latest version of the
“Principles of genetic testing” was issued by the SSMG
Board on March 2, 2012. It builds upon and cites impor-
tant international guidelines and other instruments in
the field, including the UNESCO declarations, European
Commission’s 25 recommendations, European Society of
Human Genetics (ESHG) recommendations on genetic
testing, Slovakian Constitution and applicable legislation
(in general), as well as the documents of the Council of Eu-
rope: Oviedo Convention (1997), Additional Protocol on
Genetic Testing for Health Purposes (2008), and the CoE’s
Recommendations: Rec. (90)13, Rec. (92)3, Rec. (97)5 and
CM/Rec.(2010). 
3. If not, is it foreseen to introduce any legislation/regu-
lations?
When drafting the extensive new health, health care and
health care system legislation in 2003 – 2004, more de-
tailed provisions for several areas of biomedicine were
proposed and debated, including e.g. more detailed pro-
visions for human genetics, human assisted reproduc-
tion, bio-banks, cloning etc. As the necessary political con-
sensus was not reached at that time, the “problematic”
(“controversial”) provisions were deleted from the legis-
lation at that time for the sake of its passing through the
parliament.  
Within the accession process of Slovakia to the European
Union, several legislation provisions had to be introdu-
ced to make for the required compatibility of the Slova-
kian with the EU law. This surely included also some pro-
visions applicable to genetic testing field. After entering
EU, Slovakia has to comply also with all EU legislation, as
required/agreed, including application of the respective
Directives into her legal system, and complying with the
directly applicable Regulations as well.
It is my guess that when health, health care legislation is
opened for more extensive amendments in the (near/more
far?) future, the questions/issues cut away within the
2003-2004 legislative processes will surely pop-up again,
especially because already at present the voices from
professional community point out the necessity of such
legislation changes/provisions. I do not think, however,
such legislative initiatives are to be expected within the
present parliament’s term, i.e. before the next future
elections in Slovakia (2016).           
4. If your country has ratified the Oviedo Convention, 
but not its Additional Protocol concerning Genetic 
Testing for Health Purposes, what are the current pos-
sible obstacles to this ratification?
There are no real obstacles, as it is understood that via its
CDBI/DH-BIO delegation Slovakia took a direct part in
the elaboration processes of the Protocol. It is also under-
stood that the Protocol is not at all contrary to any provi-
sion in the applicable Slovak law. However, the ratifica-
tion is not seen as a strong priority at present, while the
Ministry is being busy with other tasks. The Additional
Protocol on Transplantation has been recently pushed
into the ratification process. I believe the Additional Pro-
tocol on Genetic Testing for Health Purposes should nor-
mally follow rather soon.   
5. What assistance could the Council of Europe provide 
to facilitate progress in your country towards the rati-
fication procedure?
I believe that hosting of this DEBRA Program conference,
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specifically devoted to the AP on Genetic Testing for
Health Purposes, by the Ministry of Health of the Slovak
Republic, even at the Ministry’s premises, with foreseen
participation/attendance of the Ministry’s officers and
leadership, may really help to appreciate the benefits of
ratification, and put the process into an appropriate mo-
vement. The necessary momentum might also be enhan-
ced by the participation of the experts/real life workers
in genetics from Slovakia, providing a good opportunity
for discussions with colleagues from other CEE count-
ries, as well as discussion among the Slovakian partici-
pants themselves, hopefully leading to a clear undersco-
ring the importance of the early on ratification.
6. If your country has already ratified the Additional Pro-
tocol, what assistance could the Council of Europe 
provide to facilitate its implementation?
Slovakia has not yet ratified this AP.
I do believe that after some ratifications are completed in
some more countries within CEE area, similar DEBRA
meeting could be organized in one of CEE countries spe-
cifically devoted to the problems/challenges of the AP
implementation. Slovakian authorities might be interested
again to host such conference.  
Responses by: Jozef Glasa
Institution: Slovak Medical University in Bratislava: Insti-
tute of Health Care Ethics, Institute of Pharmacology and
Clinical Pharmacology; Institute of Medical Ethics and
Bioethics n. f.; Bratislava
SLOVENIA
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): ratified.
2. Does your country have any legislation or regulations 
covering genetic testing for health purposes?
At this point there is no national legislation or regula-
tions.
3. If not, is it foreseen to introduce any legislation/regu-
lations?
Yes, it is in the phase of preparation.
4. If your country has ratified the Oviedo Convention, 
but not its Additional Protocol concerning Genetic 
Testing for Health Purposes, what are the current 
possible obstacles to this ratification?
Slovenia ratified the Additional Protocol.
5. If your country has already ratified the Additional Pro-
tocol, what assistance could the Council of Europe pro-
vide to facilitate its implementation?
– regulation in the field of direct to consumer genetic 
testing, 
– following/promoting strict rules about genetic tes-
ting and counselling – who is competent (?), 
– public actions? informing lay public?
Responses by: Luca Lovrecic
Institution: Clinical Institute Of Medical Genetics, 
University Medical Center Ljubljana
TURKEY
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): ratified.
2. Does your country have any legislation or regulations 
covering genetic testing for health purposes?
Regulation of the Diagnostics Centres for Genetic Diseases.
This regulation covers; the diagnosis centres which apply
pre-natal and/or post-natal methods for genetic diseases,
those public institutions and organizations, and private
legal entities and people who run the said diagnosis cent-
res, and their activities as well. In the scope of this regu-
lation, the health related tests only can be carried out,
and a consent form is requested for each test from the
patient. Genetic counselling is provided for each patient.
Test results are delivered to the patient only, and not sa-
ved to the health database.
3. If your country has ratified the Oviedo Convention, 
but not its Additional Protocol concerning Genetic Tes-
ting for Health Purposes, what are the current possib-
le obstacles to this ratification? 
The assessment process regarding the above mentioned
additional protocol is still continuing in consultation
with the scientists from the universities in our country.
4. What assistance could the Council of Europe provide 
to facilitate progress in your country towards the rati-
fication procedure?
At present, we have no request from the Council of Europe
for any assistance in this regard. We would like to express
our appreciation for their previous support.
Responses by: Demet Tass
Institution: The Ministry of Health of Turkey
UKRAINE
1. Convention on Human Rights and Biomedicine (Ovie-
do Convention): not ratified.
2. Does your country have any legislation or regulations co-
vering genetic testing for health purposes? Please specify.
Yes. Regulations for genetic testing for infertile couples,
women with miscarriages etc.
3. What assistance could the Council of Europe provide 
to facilitate progress in your country towards the rati-
fication procedure?
The ratification procedure strongly depends on the Par-
liament of Ukraine. Many times Oviedo Convention was
submitted for consideration, but strong lobby cancelled
it. Ukraine needs well prepared information campaign all
over the country. When people will understand the con-
tent and importance of the Convention and its Additio-
nal Protocols, then it will be impossible to decline the
ratification. Right now, the problems of bioethics are not
understood by the common people in Ukraine.
Name: Natalya Silina
Institution: Department of Medical and Psycho-Social
Problems of Family, Institute of Pediatrics, Obstetrics
and Gynecology
Article 20 – Public information
Parties shall take appropriate measures to facilitate access
for the public to objective general information on gene-
tic tests, including their nature and the potential impli-
cations of their results.
Article 22 – Wider protection
None of the provisions of this Protocol shall be inter-
preted as limiting or otherwise affecting the possibility
for a Party to grant persons concerned by genetic testing
for health purposes a wider measure of protection than
is stipulated in this Protocol.
Additional Protocol to the Convention on Human Rights and Biomedi-
cine, concerning Genetic Testing for Health Purposes (2008)
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CONCLUSIONS OF THE ROUND TABLE
Participants wanted to highlight following points coming
out from their discussions and sharing of information at
the conference about respective challenges in their count-
ries with regard to the genetic tests for health purposes,
especially concerning health policy and ethical issues
involved, as well as the needs of even a better protection
of human dignity, fundamental rights and respective inte-
rests of their citizens, when implementing these novel, po-
werful tools in everyday’s medicine and health care.     
1. Participants found the exchange of information on 
the realities of respective situations in the area of ge-
netic tests conducted for health purposes in their 
countries particularly useful and interesting. Besides un-
derstandable differences, many similarities among 
their respective situations, understanding of existing 
deficiencies and shortcomings, emerging needs and 
perspectives, as well as the novel, common challenges, 
were identified. Within the laudable efforts, witnes-
sed in the countries of Central and Eastern Europe, 
being aimed at an appropriate, useful and safe applica-
tion of genetic tests and medical genetics services, fol-
lowing points might be of particular practical interest:    
● organization of genetic services to improve efficiency 
– in terms of pooling precious resources – material, 
equipment and expertise, by their appropriate centrali-
zation;
● regional collaboration between countries to rely on 
specific expertise to cover broader necessary spectrum 
of the genetic services; 
● private – public dichotomy of genetic services: issues 
of quality, equity of access, privacy and other individual 
concerns protection;
● education and training – some serious gaps exist; the-
re is a strong need for appropriate capacity building – 
training of the expert health personnel, especially for 
genetic counselling; having an internationally recogni-
zed, harmonised curriculum in medical genetics may 
be useful;
● education, information of the general public and of the 
health care professionals, doctors in general (i.e. of the 
“non-geneticists”) need to be improved and should in-
clude the relevant ethical and legal aspects; 
● patients driven developments are to prevail in the clo-
ser future – probably not so much those of the techno-
logy driven; an appropriate balance should be sought 
and achieved, however, between the real needs and 
possibilities, including sustainability, to adequately ad-
dress and meet the needs of the patients and of the so-
ciety, while dealing effectively with the false hopes and 
unrealistic hypes introduced within the boom of an un-
restricted commercialization;    
● legal situations might be characterized by some gaps 
here and there, but even a more pressing problem 
seems to be the effective implementation and enfor-
cement of existing – and forthcoming legal provisions 
in real life practice; while still not having effective 
enough and reliable control mechanisms in place that 
would be able to provide the necessary oversight;   
● genetic tests offered by private companies, someti-
mes well-hidden from an official oversight, the pheno-
menon that is increasing at a great speed, including 
direct-to-consumer advertising and selling via Inter-
net, still characterized by a very speedy evolution of tech-
nologies; hereby, insufficient or inadequate, or none 
consultation services are available; this may substan-
tially increase the risks of potentially serious conse-
quences for the lay customers/users/patients; also the  
protection of privacy could be an issue in such poorly 
controlled commercial settings; 
● strong markets exist, and still grow, for genetic testing 
(too frequently without proper counselling possibili-
ties), therefore, having a proper legislation in place may 
help to prevent potentially serious future problems 
(those in the respective health policy, medical, ethical 
and legal realms).
2. Participants acknowledged several perceived benefits 
of the prospective ratifications of the Additional Pro-
tocol to Oviedo Convention concerning Genetic Tes-
ting for Health Purposes by their respective count-
ries, especially from the point of view of positive and 
more streamlined developments of their countries’ own 
legislations, currently rather under-developed in this 
area. In the countries, where ratification of the Ovie-
do Convention and its Additional Protocols had been 
in a more active progress, the positive influence upon 
the national legislation development and implementa
tion may be documented. The participants also stres-
sed the need for closer work with their state autho-
rities, and parliaments, to enhance and speed up the 
ongoing, or still just planned, ratification processes. 
In these efforts, positive activities, channelled by ap-
propriate Council of Europe structures, might be very 
helpful. 
3. Participants noted a relatively frequent lack of politi-
cal and public interest, experienced in their count-
ries, sometimes caused by a low, or inadequate pub-
lic, or even professional awareness and education levels, 
as well as by some specific characteristics of the natio-
nal legislation systems and processing, as main reasons 
for somewhat delayed and slow ratification progress 
concerning the Convention and the Additional Proto-
cols in general, and the Additional Protocol concerning
Genetic Tests for Health Purposes in particular. In 
this respect, awareness building and more effective in-
formation and educational activities at the national 
levels, possibly with an international (or international - 
regional) input and support seem to be both useful and 
necessary.      
4. The usefulness and importance of regional conferen-
ces, such as the one just held in Bratislava within the 
Council of Europe DEBRA Program, was gratefully 
acknowledged and underlined. It is necessary to pro-
vide an adequate political and economic support for 
similar endeavours in the future. Despite the “regional” 
international aspects are of utmost importance for 
the present and for the near future time being, input 
providing truly European, or even broader (global) in-
ternational perspective (as was the case also with the 
contributions of the internationally renowned invited 
speakers at this conference), does seem to be equally, 
and even increasingly important.                 
Based on the compilation of the delegations’ interventions col-
lected during the roundtable discussions held during the second
day of the conferenced, i.e. on May 29 – 30, 2014. 
Edited by Jozef Glasa.
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